Movatterモバイル変換


[0]ホーム

URL:


EP3639733B1 - Apparatus for monitoring cardio-pulmonary health - Google Patents

Apparatus for monitoring cardio-pulmonary health
Download PDF

Info

Publication number
EP3639733B1
EP3639733B1EP19191677.4AEP19191677AEP3639733B1EP 3639733 B1EP3639733 B1EP 3639733B1EP 19191677 AEP19191677 AEP 19191677AEP 3639733 B1EP3639733 B1EP 3639733B1
Authority
EP
European Patent Office
Prior art keywords
patient
movement
signal
cardio
respiratory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19191677.4A
Other languages
German (de)
French (fr)
Other versions
EP3639733A2 (en
EP3639733A3 (en
Inventor
Klaus Henry Schindhelm
Steven Paul Farrugia
Michael Waclaw COLEFAX
Faizan JAVED
Rami KHUSHABA
Conor Heneghan
Philip De Chazal
Alberto Zaffaroni
Niall Fox
Patrick Celka
Emer O'HARE
Stephen James REDMOND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resmed Sensor Technologies Ltd
Original Assignee
Resmed Sensor Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902693Aexternal-prioritypatent/AU2012902693A0/en
Application filed by Resmed Sensor Technologies LtdfiledCriticalResmed Sensor Technologies Ltd
Priority to EP22202980.3ApriorityCriticalpatent/EP4154804A1/en
Publication of EP3639733A2publicationCriticalpatent/EP3639733A2/en
Publication of EP3639733A3publicationCriticalpatent/EP3639733A3/en
Application grantedgrantedCritical
Publication of EP3639733B1publicationCriticalpatent/EP3639733B1/en
Activelegal-statusCriticalCurrent
Anticipated expirationlegal-statusCritical

Links

Images

Classifications

Definitions

Landscapes

Description

    6.1 (1) FIELD OF THE INVENTION
  • The present technology relates to one or more of the diagnosis, treatment and amelioration of respiratory disorders, and to procedures to prevent respiratory disorders. In particular, the present technology relates to medical devices, and their use for treating respiratory disorders and for preventing respiratory disorders.
  • 6.2 (2) DESCRIPTION OF THE RELATED ART
  • The respiratory system of the body facilitates gas exchange. The nose and mouth form the entrance to the airways of a patient.
  • The airways include a series of branching tubes, which become narrower, shorter and more numerous as they penetrate deeper into the lung. The prime function of the lung is gas exchange, allowing oxygen to move from the air into the venous blood and carbon dioxide to move out. The trachea divides into right and left main bronchi, which further divide eventually into terminal bronchioles. The bronchi make up the conducting airways, and do not take part in gas exchange. Further divisions of the airways lead to the respiratory bronchioles, and eventually to the alveoli. The alveolated region of the lung is where the gas exchange takes place, and is referred to as the respiratory zone. See West, Respiratory Physiology- the essentials.
  • A range of cardio-pulmonary disorders exist.
  • Obstructive Sleep Apnea (OSA), a form of Sleep Disordered Breathing (SDB), is characterized by occlusion of the upper air passage during sleep. It results from a combination of an abnormally small upper airway and the normal loss of muscle tone in the region of the tongue, soft palate and posterior oropharyngeal wall during sleep. The condition causes the affected patient to stop breathing for periods typically of 30 to 120 seconds duration, sometimes 200 to 300 times per night. Itoften causes excessive daytime somnolence, and it may cause cardiovascular disease and brain damage. The syndrome is a common disorder, particularly in middle aged overweight males, although a person affected may have no awareness of the problem. SeeUS Patent 4,944,310 (Sullivan).
  • Periodic or modulated breathing, for example Cheyne-Stokes Respiration (CSR), is a disorder of a patient's respiratory controller in which there are rhythmic alternating periods of waxing and waning ventilation (hyperpneas and apneas / hypopneas), causing repetitive de-oxygenation and re-oxygenation of the arterial blood. It is possible that CSR is harmful because of the repetitive hypoxia. In some patients CSR is associated with repetitive arousal from sleep, which causes severe sleep disruption, increased sympathetic activity, and increased afterload. SeeUS Patent 6,532,959 (Berthon-Jones).
  • Obesity Hyperventilation Syndrome (OHS) is defined as the combination of severe obesity and awake chronic hypercapnia, in the absence of other known causes for hypoventilation. Symptoms include dyspnea, morning headache and excessive daytime sleepiness.
  • Chronic Obstructive Pulmonary Disease (COPD) encompasses any of a group of lower airway diseases that have certain characteristics in common. These include increased resistance to air movement, extended expiratory phase of respiration, and loss of the normal elasticity of the lung. Examples of COPD are emphysema and chronic bronchitis. COPD is caused by chronic tobacco smoking (primary risk factor), occupational exposures, air pollution and genetic factors. Symptoms include: dyspnea on exertion, chronic cough and sputum production.
  • Neuromuscular Disease (NMD) is a broad term that encompasses many diseases and ailments that impair the functioning of the muscles either directly via intrinsic muscle pathology, or indirectly via nerve pathology. Some NMD patients are characterised by progressive muscular impairment leading to loss of ambulation, being wheelchair-bound, swallowing difficulties, respiratory muscle weakness and, eventually, death from respiratory failure. Neuromuscular disorders can be divided into rapidly progressive and slowly progressive: (i) Rapidly progressive disorders: Characterised by muscle impairment that worsens over months and results in death within a few years (e.g. Amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy (DMD) in teenagers); (ii) Variable or slowly progressive disorders: Characterised by muscle impairment that worsens over years and only mildly reduces life expectancy (e.g. Limb girdle, Facioscapulohumeral and Myotonic muscular dystrophy). Symptoms of respiratory failure in NMD include: increasing generalised weakness, dysphagia, dyspnea on exertion and at rest, fatigue, sleepiness, morning headache, and difficulties with concentration and mood changes.
  • Chest wall disorders are a group of thoracic deformities that result in inefficient coupling between the respiratory muscles and the thoracic cage. The disorders are usually characterised by a restrictive defect and share the potential of long term hypercapnic respiratory failure. Scoliosis and/or kyphoscoliosis may cause severe respiratory failure. Symptoms of respiratory failure include: dyspnea on exertion, peripheral oedema, orthopnea, repeated chest infections, morning headaches, fatigue, poor sleep quality and loss of appetite.
  • Heart failure is a relatively common and severe clinical condition, characterised by the inability of the heart to keep up with the oxygen demands of the body. Management of heart failure is a significant challenge to modem healthcare systems due to its high prevalence and severity. Heart failure is a chronic condition, which is progressive in nature. The progression of heart failure is often characterized as relatively stable over long periods of time (albeit with reduced cardiovascular function) punctuated by episodes of an acute nature. In these acute episodes, the patient experiences worsening of symptoms such as dyspnea (difficulty breathing), gallop rhythms, increased jugular venous pressure, and orthopnea. This is typically accompanied by overt congestion (which is the buildup of fluid in the pulmonary cavity). This excess fluid often leads to measurable weight gain of several kilograms. In many cases, however, by the time overt congestion has occurred, there are limited options for the doctor to help restabilize the patients, and in many cases the patient requires hospitalization. In extreme cases, without timely treatment, the patient may undergo acute decompensated heart failure (ADHF).
  • 6.2.1 Therapy
  • Nasal Continuous Positive Airway Pressure (CPAP) therapy has been used to treat Obstructive Sleep Apnea (OSA). The hypothesis is that continuous positive airway pressure acts as a pneumatic splint and may prevent upper airway occlusion by pushing the soft palate and tongue forward and away from the posterior oropharyngeal wall.
  • Non-invasive ventilation (NIV) has been used to treat CSR, OHS, COPD, NMD and Chest Wall disorders.
  • 6.2.2 PAP Device
  • The air at positive pressure under CPAP therapy is typically supplied to the airway of a patient by a PAP device such as a motor-driven blower. The outlet of the blower is connected via a flexible delivery conduit to a patient interface such as a mask.
  • 6.2.3 Monitoring systems
  • It is of interest to be able to predict potential cardio-pulmonary events such as ADHF events with a view to preventing or ameliorating such events.Characteristics that have been proposed or used for the purpose of predicting cardio-pulmonary events include body weight, levels of B natriuretic peptides (BNP), nocturnal heart rate, changes in sleeping posture, and changes in respiration. Polysomnography (PSG) is a conventional system for diagnosis and prognosis of cardio-pulmonary disorders. In addition, contact sensor modalities such as masks or oronasal cannulae with capability for monitoring and analysing respiratory parameters during sleep to determine the severity of sleep disordered breathing are known. However, such systems are complicated and potentially expensive, and / or may be uncomfortable or impractical for a patient at home trying to sleep. < insert new page 5a >
  • 7 (G) BRIEF SUMMARY OF THE TECHNOLOGY
  • The subject-matter of the invention is defined by the features ofindependent claim 1 Further preferred embodiments of the present invention are defined in the dependent claims.
  • The present technology is directed towards providing medical devices for use in the diagnosis and prognosis of cardio-pulmonary disorders having one or more of improved comfort, cost, efficacy, ease of use and manufacturability.
  • A first aspect of the present technology relates to apparatus used in the diagnosis and prognosis of a cardio-pulmonary disorder.
  • Another aspect of the present technology relates to methods used in the diagnosis and prognosis of a cardio-pulmonary disorder.
  • One form of the present technology comprises cardio-pulmonary health monitoring apparatus and methods for monitoring cardio-pulmonary health of a patient that extract features indicative of the severity of sleep disordered breathing by a patient from movement signal(s) obtained from a contactless motion sensor representing bodily movement of the patient, and uses the extracted features to predict whether a clinical event is likely to occur during a predetermined prediction horizon.
  • Another aspect of one form of the present technology is cardio-pulmonary health monitoring apparatus and methods that analyse sensor data related to cardio-pulmonary health, generate a query for display to a patient based on the analysis, and generate a clinical alert based on a response to the query.
  • Another aspect of one form of the present technology is cardio-pulmonary health monitoring apparatus and methods that analyse respiratory parameters extracted from sensor data and generate a potential relapse alert based on the analysis.
  • US 2006/030890 A1 discloses a system for verification of an alert generated by an assessment process operating upon patient feedback and physiological data. The system may utilize a categorization for alerts, in order to obtain a rule set corresponding thereto. A question hierarchy may correspond to each rule within the rule set. Each question hierarchy may be posed to the patient to verify the alarm.
  • US 2010/010358 A1 discloses a system and method for the detection of acute myocardial infarction (AMI) using a staged approach for accurate and rapid detection. Physiological signals in a patient's body are sensed and corresponding physiological parameters are derived in a staged approach in order to determine the probability that AMI is occurring in a patient in a first detection stage. If the computed probability from physiological signals indicates the possibility of AMI, then the patient is prompted, such as through a patient-wearable device, to answer specific AMI-related questions to assist in diagnosis of AMI in a second stage.
  • WO 2011/149570 A1·relates to a system for monitoring patients, and more specifically post-operative patients receiving narcotics.
  • US 2007/161913 A1 discloses a method for relating to each other cardiovascular and sleep disordered breathing conditions of a patient. The patient's heart rate and/or detailed echocardiogram data is monitored and recorded continuously or periodically together with sleep disordered breathing information on similar time scales. Changes in the patient's heart rate associated with changes in sleep disordered breathing can then be observed.
  • Another aspect of one form of the present technology is cardio-pulmonary health monitoring apparatus and methods that extract features indicative of the severity of sleep disordered breathing from movement signal(s) obtained from a contactless motion sensor representing bodily movement of the patient.
  • Of course, portions of the aspects may form sub-aspects of the present technology. Also, various ones of the sub-aspects and/or aspects may be combined in various manners and also constitute additional aspects or sub-aspects of the present technology.
  • Other features of the technology will be apparent from consideration of the information contained in the following detailed description, abstract, drawings and claims.
  • 8 (H) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
  • The present technology is illustrated by way of example, and not by way of limitation, in the figures of the accompanying drawings, in which like reference numerals refer to similar elements, including:
    8.1 TREATMENT SYSTEMS
    • Fig. 1a shows an example system suitable for implementation with in accordance with the present technology. Apatient 1000 wearing apatient interface 3000, receives a supply of air at positive pressure from aPAP device 4000. Air from the PAP device is humidified in ahumidifier 5000, and passes along anair circuit 4170 to thepatient 1000.
      8.2 MONITORING SYSTEMS
    • Fig. 1b shows a contactless sensorunit monitoring a sleeping patient.
      8.3 RESPIRATORY SYSTEM
    • Fig. 2a shows an overview of a human respiratory system including the nasal and oral cavities, the larynx, vocal folds, oesophagus, trachea, bronchus, lung, alveolar sacs, heart and diaphragm.
    • Fig. 2b shows a view of a human upper airway including the nasal cavity, nasal bone, lateral nasal cartilage, greater alar cartilage, nostril, lip superior, lip inferior, larynx, hard palate, soft palate, oropharynx, tongue, epiglottis, vocal folds, oesophagus and trachea.
      8.4 PATIENT INTERFACE
    • Fig. 3a shows a patient interface in accordance with one form of the present technology.
      8.5 PAP DEVICE
    • Fig. 4a shows a PAP device in accordance with one form of the present technology.
      8.6 HUMIDIFIER
    • Fig. 5a shows a humidifier in accordance with one aspect of the present technology.
      8.7 BREATHING WAVEFORMS
    • Fig. 6a shows a model typical breath waveform of a person while sleeping. The horizontal axis is time, and the vertical axis is respiratory flow. While the parameter values may vary, a typical breath may have the following approximate values: tidal volume,Vt, 0.5L, inhalation time,Ti, 1.6s, peak inspiratory flow,Qpeak, 0.4 L/s, exhalation time,Te, 2.4s, peak expiratory flow,Qpeak, -0.5L/s. The total duration of the breath,Ttot, is about 4s. The person typically breathes at a rate of about 15 breaths per minute (BPM), with Ventilation,Vent, about 7.5 L/minute. A typical duty cycle, the ratioof Ti toTtot is about 40%.
    • Fig. 6b shows a patient during Non-REM sleep breathing normally over a period of about ninety seconds, with about 34 breaths. This being treated with Automatic PAP, and the mask pressure was about 11 cmH2O. The top channel shows oximetry (SpO2), the scale has a range of saturation from 90 to 99% in the vertical direction. The patient maintained a saturation of about 95% throughout the period shown. The second channel shows quantitative respiratory airflow, and the scale ranges from -1 to +1 LPS in a vertical direction, and with inspiration positive. Thoracic and abdominal movement are shown in the third and fourth channels.
    • Fig. 6c shows polysomnography of a patient There are eleven signal channels from top to bottom with a 6 minute horizontal span. The top two channels both are EEG (electoencephalogram) from different scalp locations. Periodic spikes in second represent cortical arousal and related activity. The third channel down is submental EMG (electromyogram). Increasing activity around time of arousals represent genioglossus recruitment. The fourth & fifth channels are EOG (electro-oculogram). The sixth channel is an electocardiogram. The seventh channel shows pulse oximetry (SpO2) with repetitive desaturations to below 70% from about 90%. The eighth channel is respiratory airflow using nasal cannula connected to differential pressure transducer. Repetitive apneas of 25 to 35 seconds alternating with 10 to 15 second bursts of recovery breathing coinciding with EEG arousal and increased EMG activity. The ninth shows movement of chest and tenth shows movement of abdomen. The abdomen shows a crescendo of movement over the length of the apnea leading to the arousal. Both become untidy during the arousal due to gross bodily movement during recovery hyperpnea. The apneas are therefore obstructive, and the condition is severe. The lowest channel is posture, and in this example it does not show change.
    • Fig. 6d shows patient flow data where the patient is experiencing a series of total obstructive apneas. The duration of the recording is approximately 160 seconds. Flow ranges from about +1 L/s to about -1.5L/s. Each apnea lasts approximately 10-15s.
    • Fig. 6e shows a patient with Cheyne-Stokes respiration. There are three channels- oxygen saturation (SpO2), a signal indicative of flow, and the third, a signal indicative of movement. The data span six minutes. The signal representative of flow was measured using a pressure sensor connected to nasal cannulae. The patient exhibits apneas of about 22 seconds alternating with hyperpneas of about 38 seconds. The higher-frequency, low-amplitude oscillation occurring during each apnea is cardiogenic.
      8.8 MONITORING APPARATUS
    • .Fig. 7ais a block diagram illustrating anapparatus,including the contactless sensor unit of Fig. 1b,for monitoring the cardio-pulmonary health of a patient.
    • Fig. 7b is a flow chart illustrating a method of monitoring the cardio-pulmonary health of a patient, as carried out by the monitoring apparatus ofFig. 7a.
    • Fig. 7c is a flow chart illustrating a method of monitoring the cardio-pulmonary health of a patient, as implemented within the monitoring apparatus ofFig. 7a.
    • Fig. 7d isa flow chart illustrating the example steps in a method of predicting clinical events from signals representative of patient movement, as may be used in the method ofFig. 7b orFig. 7c.
    • Fig. 7e is a block diagram illustrating the example modules that may serve to implement making up the feature extraction step in the method ofFig. 7d and their relationship under the combined or single-channelapproach in one form of the present technology.
    • Fig. 7f is a block diagram illustrating the examplemodules making up that may serve to implement the feature extraction step in the method ofFig. 7d and their relationship under the hybridapproach in one form of the present technology.
    • Fig. 7g illustrates Lotjonen pattern expansion as applied during one implementation of the sleep / wake analysis module ofFig. 7e and7f.
    • Fig. 7h is a flow chart illustrating a method of setting a waveform length threshold in an alternative implementation of the sleep / wake analysis module ofFigs. 7e and7f.
    • Fig. 7i contains illustrations of examples of three generic SDB respiratory effort reduction templates.
    • Fig. 7j is a flow chart illustrating a method that may be used to implement of the prediction step of the method ofFig. 7d.
    9 (I) DETAILED DESCRIPTION OF EXAMPLES OF THE TECHNOLOGY
  • Before the present technology is described in further detail, it is to be understood that the technology is not limited to the particular examples described herein, which may vary. It is also to be understood that the terminology used in this disclosure is for the purpose of describing only the particular examples discussed herein, and is not intended to be limiting.
  • 9.1 TREATMENT SYSTEMS
  • In one form, the present technology comprises apparatus for treating a cardio-pulmonary disorder. The treatment apparatus may comprise aPAP device 4000 for supplying pressurised respiratory gas, such as air, to thepatient 1000 via an air delivery tube leading to apatient interface 3000.
  • 9.2 THERAPY
  • Disclosed but not part of the invention as defined by the appended claims is a method for treating a respiratory disorder comprising the step of applying positive pressure to the entrance of the airways of apatient 1000.
  • 9.3 PAP DEVICE4000
  • APAP device 4000 in accordance with one aspect of the present technology comprises mechanical and pneumatic components 4100,electrical components 4200 and is programmed to execute one or more processes4300. The PAP device preferably has anexternal housing 4010, preferably formed in two parts, anupper portion 4012 of theexternal housing 4010, and alower portion 4014 of theexternal housing 4010. In alternative forms, theexternal housing 4010 may include one or more panel(s) 4015. Preferably thePAP device 4000 comprises achassis 4016 that supports one or more internal components of thePAP device 4000. In one form a pneumatic block 4020 is supported by, or formed as part of thechassis 4016. ThePAP device 4000 may include ahandle 4018.
  • 9.4HUMIDIFIER 5000
  • In one form of the present technology there is provided ahumidifier 5000 comprising a water reservoir 5110, and a heating plate 5120.
  • 9.5 MONITORING APPARATUS7000
  • In one form, the present technology comprisesapparatus 7000 for monitoring the cardio-pulmonary health of a patient. Theapparatus 7000 comprises acontactless sensor unit 1200 positioned adjacent and relatively close to a sleeping patient 1000 (e.g. on a bedside table), as illustrated in Fig. 1b.
  • Heart failure has been shown to be highly correlated with sleep disordered breathing (SDB). In particular, Cheyne-Stokes respiration (CSR), an example of which is illustrated inFig. 6e, is caused in general by an instability in the body's respiratory control system, one cause of which is heart failure. In addition, features indicative of the severity of OSA such as the Apnea / Hypopnea Index (AHI) have been shown to be independent predictors of death by, and hospitalization for, ADHF events. Therefore, one approach to predicting ADHF events is to use features that indicate the severity of sleep disordered breathing, i.e. SDB features. One example of SDB features may be a set of features that indicate the extent to which respiration during sleep resembles classic CSR, i.e. "Cheyne-Stokes-like" features. The values of and changes in such SDB features may contain useful information about the likelihood of ADHF events. The disclosedmonitoring apparatus 7000 is therefore configured to extract and analyse features indicative of the severity of sleep disordered breathingof thepatient 1000, i.e. SDBfeatures. In some cases, such features may be determined in accordance with any of the methodologies described in International Publication NumberWO 2006/066337 filed on 21 December 2005.
  • Moreover, Cheyne-Stokes respiration features may also be a short term marker of changes during the acute phase of a decompensation event of a heart failure patient (a decompensation event occurs when the compensatory mechanisms that the heart uses to maintain adequate cardiac output, are no longer sufficient - these decompensations can lead to a rapid worsening of symptoms and often require hospitalization). The medical response to a decompensation is often to temporarily increase diuretic use, and hence remove excess fluid. This can cause consequent changes in the breathing parameters, and hence the "Cheyne-Stokes-like" features described above could be used for assessing short-term effectiveness of treatments. As a specific example, the modulation cycle length of the Cheyne-Stokes respiration can be correlated with the circulation delay of the body (e.g., seeDai Yumino and T. Douglas Bradley "Central Sleep Apnea and Cheyne-Stokes Respiration", Proceedings of the American Thoracic Society, Vol. 5, No. 2 (2008), pp. 226-236.) and hence be used as a prognostic marker.
  • 9.5.1 Components
  • Fig. 7a is a blockdiagram illustrating anapparatus 7000, including thecontactless sensor unit 1200 of Fig. 1b, for monitoring the cardio-pulmonary health of a patient 1000in more detail according to one form of the present technology. In theapparatus 7000, thecontactless sensor unit 1200 includes acontactless motion sensor 7010 generally directed toward the patient 1000.Themotion sensor 7010 is configured to generate one or more signals representing bodily movement of thepatient 1000, from which may be obtained one or more signals representing respiratory movement of the patient.
  • Thesensor unit 1200 may also include a microcontroller unit (MCU) 7001, memory 7002 (e.g. a memory card) for logging data. In one implementation, thesensor unit 1200 includescommunications circuitry 7004 configured to transfer data to an external computing device7005, e.g. a local general purpose computer, or a remote server, via aconnection 7008. Theconnection 7008 may be wired or wireless, in which case thecommunications circuitry 7004 has wireless capability, and may be direct or indirect via a local network or a wide-area network such as the Internet (not shown).
  • Thesensor unit 1200 includes aprocessor 7006 configured to process thesignals generated by themotion sensor 7010 as described in detail below.
  • Thesensor unit 1200 includes a display device 7015configured to provide visual feedback to a user. In one implementation, thedisplay device 7015 comprises one or more warning lights (e.g., one or more light emitting diodes). Thedisplay device 7015 may also be implemented as a display screen such as an LCD or a touch-sensitive display. Operation of the display device 7015is controlled by theprocessor 7006 based on an assessment of the patient's cardio-pulmonary health. Thedisplay device 7015 may be implemented to visually show information to a user of themonitoring apparatus 7000,such as a patient or a physician or other clinician. Thedisplay device 7015 may also display a graphical user interface for operation of themonitoring apparatus 7000.
  • Thesensor unit 1200 includesan audio output 7017configured to provide acoustic feedback to a user under the control of theprocessor 7006, e.g., a tone whose frequency varies with breathing, or an alarm which sounds when certain conditions are met.
  • User control of the operation of themonitoring apparatus 7000 may be based on operation of controls(not shown) that are sensed by theprocessor 7006 of themonitoring apparatus 7000.
  • One example of asensor unit 1200 is the SleepMinder device manufactured by ResMed Sensor Technologies Ltd, which contains a contactless Doppler radio-frequency (RF)motion sensor 7010.
  • In one form of the present technology, such as when the SleepMinder device is used as thesensor unit 1200, themotion sensor 7010 includesanRFtransmitter 7020 configured to transmit anRFsignal 7060.The radio-frequency signal 7060 for example has the formst=utcos2πƒct+θ
    Figure imgb0001
  • In Eq. 1, the carrier frequency isfc (typically in therange 100 MHz to 100 GHz, e.g. 3GHz to 12GHz, e.g. 5.8 GHz or 10.5 GHz),t is time,θ is an arbitrary phase angle, andu(t) is a pulse shape. In a continuous wave system, the magnitude ofu(t) may be unitary, and can be omitted from Eq. 1. More generally, the pulseu(t) will be defined as in Eq. 2:ut={1,tkT,kT+Tp,kZ0,otherwise
    Figure imgb0002

    whereT is the period width, andTp is the pulse width. WhereTp<<T, this becomes a pulsed continuous wave system. In one case, asTp becomes very small, the spectrum of the emitted signal becomes very wide, and the system is referred to as an ultra-wideband (UWB) radar or impulse radar. Alternatively, the carrier frequency of the RF transmittedsignal 7060 can be varied (chirped) to produce a so-called frequency modulated continuous wave (FMCW) system.
  • The radio frequency signal 7060may be generated by thetransmitter 7020 using alocal oscillator 7040 coupled with circuitry for applying the pulse gating. In the FMCW case, a voltage-controlled oscillator is used together with a voltage-frequency converter to produce the RF signal 7060for transmission. The coupling of the transmitted RF signal 7060to the air may be accomplished using anantenna 7050. Theantenna 7050 can be omnidirectional (transmitting power more-or-less equally in all directions) or directional (transmitting power preferentially in certain directions). It may be advantageous to use adirectional antenna 7050 in theapparatus 7000 so that transmitted and reflected energy are primarily coming from one direction. In one implementation of theapparatus 7000, asingle antenna 7050 is used for both thetransmitter 7020 and thereceiver 7030, with a single carrier frequency. Alternatively, multiple receive and transmitantennas 7050 can be used, with multiple carrier frequencies.
  • Theapparatus 7000 is compatible in various embodiments with various types ofantenna 7050 such as simple dipole antennas, patch antennas, and helical antennas, and the choice of antenna can be influenced by factors such as the required directionality, size, shape, or cost. It should be noted that theapparatus 7000 can be operated in a manner which has been shown to be safe for human use. Theapparatus 7000 has been demonstrated with a total system emitted average power of 1 mW (0 dBm) and lower. The recommended safety level for RF exposure is 1 mW/cm2. At a distance of 1 meter from a system transmitting at0 dBm, the equivalent power density will be at least 100 times less than this recommended limit.
  • In use, the transmittedRF signal 7060 is reflected off objects that reflect radio waves (such as the air-body interface of the patient 1000), and some of the reflectedsignal 7070 will be received at areceiver 7030, which can be collocated with thetransmitter 7020, or which can be separate from thetransmitter 7020, in a so-called "bistatic" configuration. The receivedsignal 7070 and the transmittedsignal 7060 can be multiplied together in a mixer 7080 (either in an analog or digital fashion). Thismixer 7080 can be of the form of a multiplier (as denoted below in (Eq. 3)) or in a circuit which approximates the effect of a multiplier (e.g., an envelope detector circuit which adds sinusoidal waves).For example, in the CW case, the mixed signal will equalmt=γcos2πƒctcos2πƒct+ϕt
    Figure imgb0003

    whereφ(t) is a phase term resulting from the path difference of the transmitted and receivedsignals 7060 and 7070 (in the case where the reflection is dominated by a single reflective object), andγ is the attenuation experienced by the reflectedsignal 7070. If the reflecting object is fixed, thenφ(t) is fixed. In theapparatus 7000, the reflecting object (e.g., the chest of the patient 1000) is in general moving, andφ(t) will be time-varying. As a simple example, if the chest is undergoing a sinusoidal motion of frequencyfmdue to respiration, then the mixed signalm(t) contains a component atfm (as well as a component centred at 2fc which can be simply removed by low pass filtering). The signal at the output of the low pass filter after mixing is referred to as the raw or demodulatedsensor signal 7003, and contains information about gross bodily (non-respiratory) movement, and respiratory movement.
  • The amplitude of the demodulatedsensor signal 7003 is affected by the mean path distance of the reflected signal, leading to detection nulls and peaks in the sensor7010 (areas where the sensor is less or more sensitive). This effect can be minimised by using quadrature techniques in which thetransmitter 7020 simultaneously transmits asignal 90 degrees out of phase(in quadrature) with thesignal 7060 of Eq. 1. This results in two reflected signals, both of which can be mixedand lowpass filtered by themixer 7080, leading to two demodulated sensor signals 7003a (the "I signal") and7003b (the "Q signal") in respective I- and Q-"channels".
  • In the UWB implementation, an alternative method of acquiring ademodulated sensor signal 7003 may be used. The path distance to the most significant air-body interface can be determined by measuring the delay between the transmitted pulse and peak reflected signal. For example, if the pulse width is 1 ns, and the distance from thesensor 7010 to the body is 0.5metres, then the delay before a peak reflection of the pulse arrives at thereceiver 7030 will be 1/(3 × 108) s = 3.33 ns. By transmitting large numbers of pulses (e.g., a 1 ns pulse every 1 µs) and assuming that the path distance is changing slowly over a given period, a demodulated sensor signal 7003may be computed as the average of the time delays over that period.
  • In this way, themotion sensor 7010, e.g., a radio-frequency sensor, can estimate the respiratory movement of the chest wall, or more generally the movement of the part of the body of thepatient 1000 whom theapparatus 7000 is monitoring.
  • As mentioned above, the receivedsignal 7070 can include large motion artefacts, e.g. as the result of gross bodily movement. This is due to the fact that the reflected signals from the body can contain more than one reflection path, and lead to complex signals (for example if one hand is moving towards the sensor, and the chest is moving away). The reception of such signals is useful as it can indicate that the upper body is in motion, which is useful in determining sleep state. The sensor can also be used to detect motion of a lower part of the body (such as involuntary leg jerks) of apatient 1000, which are useful in the diagnosis of sleep disorders such as Restless Legs Syndrome or Periodic Limb Movements.
  • In order to improve the quality of the respiratory movement signal, and more general bodily movement signals, the physical volume from which reflected energy is collected by thesensor unit 1200 can be restricted using various methods. For example, the sensor unit 1200can be made "directionally selective" (that is, it transmits more energy in certain directions), as can the antenna of thereceiver 7030. Directional selectivity can be achieved usingdirectional antennas 7050, ormultiple RF transmitters 7020. In alternative forms of the present technology, a continuous wave, an FMCW, or a UWB radar is used to obtain similar signals. A technique called "time-domain gating" can be used to only measure reflectedsignals 7070 which arise from signals at a certain physical distance from thesensor unit 1200. Frequency domain gating (filtering) can be used to ignore motions of the reflected object above a certain frequency.
  • In implementations of theapparatus 7000 using multiple frequencies (e.g., at 500 MHz and 5 GHz), the lower frequency can be used to determine large motions accurately without phase ambiguity, which can then be subtracted from the higher-frequency sensor signals (which are more suited to measuring small motions). Using such asensor unit 1200, theapparatus 7000 collects information from thepatient 1000, and uses that information to determine respiratory movement, and more general bodily movement information.
  • Other contactless motion sensors, e.g. infrared sensors, ultrasound sensors, optical sensors, or contact motion sensors, such as piezoelectric sensors or respiratory inductance plethysmographs, may be used as additional motion sensors to, thecontactless motion sensor 7010, either as part of thesensor unit 1200, or as part of a separate sensor unit Such additional motion sensorsneed to be positioned relative to thepatient 1000 in accordance with the characteristics of the respective motion sensors. For example, if the motion sensor is a respiratory inductance plethysmograph, the sensor may be positioned around the chest or abdomen of thepatient 1000. If the motion sensor is a piezoelectric sensor, or a direct air-mat pressure sensor, such asensor may be positioned under the mattress of thepatient 1000.
  • In certain implementations, one or more contactless non-motion sensors configured to provide data relevant to the cardio-pulmonary health of thepatient 1000 may be incorporated into theapparatus 7000 to enhance overall accuracy or provide additional robustness. One example of a contactless non-motion sensors is a sound sensors. The characteristic sound patterns associated with sleep apnea may be analysed and used to enhance the accuracy of the generated summary measures of SDB. The system described byKarunajeewa A.S., Abeyratne U.R., Hukins C. in "Silence-breathing-snore classification from snore-related sounds", Physiol. Meas. 29(2):227-43 (February 2008), is one example of acoustic-based screening for SDB, and such techniques could be readily incorporated into with theapparatus 7000 to provide a useful and robust tool for monitoringcardio-pulmonary health. The advantage of such incorporation is that the respiratory movement signal may be occasionally unusable due to excessive motion artefacts. At such times, the acoustic signal may provide reasonable estimates of respiratory parameters. Conversely, the acoustic signal may sometimes be unusable due to background noise contamination, at which times respiratory movement takes over as the primary sensor modality.
  • In still other implementations, theapparatus 7000 may incorporate one or more contact non-motion sensorsconfigured to provide data relevant to the cardio-pulmonary health of thepatient 1000. Examples of such contact sensors include an oximeter (which measures blood oxygen levels), an oronasal cannula (which directly measures respiratory airflow), and an electrocardiogram (ECG) monitor. An ECG monitor may be configured to detect cardiac-related characteristics such as a heart rate and may also determine respiratory parameters (such as central or obstructive apneas, hypopneas, etc.) Optionally, these parameters may be computed by theprocessor 7006 based on ECG data transmitted to theprocessor 7006, or they may be computed by the ECG monitor and be transmitted to theprocessor 7006. The oximetry sensor highlighted above has the advantage that it can also provide a respiratory effort signal; such a signal can be derived from the underlying photoplethysmogram (PPG) component of the oximeter by tracking the peak and trough values of the PPG.
  • Further parameters of clinical significance relate to the position and orientation of the patient. It has been shown that rostral fluid shift can affect the incidence of central and obstructive events (see e.g., "Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea".White LH, Bradley TD. J Physiol. 2013). In practice, heart failure patients are also intuitively aware of this phenomenon and often use pillows to prop themselves up at an angle to reduce fluid build-up and hence enhance ease of breathing during sleep. Furthermore, the likelihood of obstructive events is often dictated by position (e.g., many patients experience more obstructive events when on their back than on their sides). Therefore, in one embodiment of the system described herein, one or more three-dimensional accelerometers can be worn by the patient which can provide information about their angle of recline, and their bodily position (supine, on left, on right, or prone). This information can be combined with the measured respiratory parameters to provide further insight into the patient status.
  • The processor 7006of thesensor unit 1200, or that of theexternal computing device 7005,processes the signals 7003acquired from the sensors, e.g. the motion sensor(s) 7010,as described in detail below.The instructions for the described processing may be stored on a computer-readable storage medium, e.g. thememory 7002 of thesensor unit 1200, and interpreted and executed by a processor, e.g. theprocessor 7006 of thesensor unit 1200. In some forms of the present technology, the processing may be carried out in "batch mode", i.e. the acquired signals7003 are stored, either inmemory 7002 of thesensor unit 1200 or in that of theexternalcomputing device 7005, for one or more complete monitoring sessions, and subsequently processed in a single batch. In one implementation, each monitoring session is one night in duration. In other forms of the present technology, the processing may be carried out in "real time" during the monitoring session.
  • It should be noted that while the functionality of themonitoring apparatus 7000 is described below as controlled by thesensor unit 1200, in other implementations theexternal computing device 7005 may implement the described functionality, based on data transmitted to it by thesensor unit 1200 and any other sensors in theapparatus 7000 as described above. In such implementations, the above descriptions of thevisual display 7015 and theaudio output 7017 apply equally to comparable elements of theexternal computing device 7005. In one example, theexternal computing device 7005 is clinician-accessible apparatus such as a multi-patient monitoring system that allows a clinician to review data from remote patient data recording devices such as themonitoring apparatus 7000. In these systems, a database may be provided to record patient monitoring data. Through such anexternal computing device 7005, clinicians may receive a report or alert that the patient may require closer observation or should be brought to hospital.
  • 9.5.2 Processes
  • Theprocessor 7006 executes processes 4300 tomonitor the patient's cardio-pulmonary health from data received from thesensor unit 1200 and any other sensors described above.
  • 9.5.2.1 Clinical alerts
  • The processes 4300may be carried out to monitor thepatient 1000 before, during, and after hospitalization. For example, heart failure and COPD patients may suffer from exacerbation or decompensation (ADHF) events. These "clinical events" may require modifications to medical treatment. Untreated exacerbation could lead to further exacerbation and potentially require hospitalization for the patient. However, if exacerbation is discovered early enough, such as at the earliest stages of its onset, it may be treated in a manner that may avoid (re-)hospitalization.
  • In one form of the present technology, theprocessor 7006 analyses the processed or received sensor data to trigger generation of a clinical alert based on features related to cardio-pulmonary health extracted from the sensor data. Additional examples of such analysis, which may include evaluation of one or more change condition indicators, are described inU.S. Patent Application No. 12/751,174, filed on March 31, 2010 andU.S. Patent Application No. 12/483,357, filed on June 12, 2009.
  • Optionally, the clinical alert may include a warning or alert message taking a number of forms. For example, theprocessor 7006, to generate a clinical alert, may activate a status light (e.g., an LED or an icon on the display device 7015) of themonitoring apparatus 7000. A more detailed message concerning the assessment of the indicator may also be displayed on thedisplay device 7015. Optionally, theprocessor 7006 may also, or alternatively, send an alert message to anexternal computing device 7005 associated with a clinician via theconnection 7008. Such a message may take the form of a wired or wireless communication. For example, theprocessor 7006 may generate an alert message via a paging system such as by automatically dialing a paging system. Theprocessor 7006 may also be configured to generate an automated voice phone call message. Theprocessor 7006 may also send the alert message by a fax transmission. In some embodiments, theprocessor 7006 may also send an alert message via any internet messaging protocol, such as an email message, or by any other internet data file transport protocol. The alert messages may even be encrypted to keep patient information confidential. A typical alert message may identify the patient. Such a message may also include data recorded by themonitoring apparatus 7000 or any other recorded patient information. Optionally, in some embodiments, the alert message may even express that the patient should be considered for additional treatment, hospitalization, or an evaluation due to the detection of a potential ADHF event or exacerbation of COPD.
  • While alert messages may be directed by theprocessor 7006 to the patient via thedisplay device 7015 of themonitoring apparatus 7000 and / or the clinician via theconnection 7008, in some embodiments, the alert messages could be directed more selectively. For example, a first alert message may be only transmitted to a clinician by only transmitting the alert message to anexternal computing device 7005 through theconnection 7008 without showing any alert on thedisplay device 7015. However, a second alert message, which may be a more urgent message, could then be actively displayed on thedisplay device 7015 in addition to being transmitted to theexternal computing device 7005. An audible alarm from an optional speaker controlled by theprocessor 7006 may also be implemented. Use of an audible alarm may depend on the urgency of the alert message.
  • 9.5.2.2 Queries
  • In another form of the present technology, the processor 7006may condition an alert on input responses to a patient query that may serve to avoid unnecessary alerts. For example, based on an analysis of sensor data by the monitoring apparatus 7000 (e.g., a comparison of one or more respiratory parameters with one or more thresholds) the processor 7006may trigger a presentation of a patient query to the patient to prompt the patient for input based on the assessment made by the processor. In such a case, thedisplay device 7015 under control of the processor 7006may present a query to the patient, prompting the patient to input additional information via a user interface. The presented question or questions of the query may be selected from a database, or other data structure of questions, such as a data structure in a memory of the apparatus, such that the selected questions are particularly associated with a pattern detected by the processor in the analysis. The processor 7006may then further evaluate data of the receivedresponses to the query. Based on this further evaluation, the processor 7006may trigger an alert message, refrain from triggering an alert message, and/or delay a triggering of an alert message pending responses to one or more additional triggered queries. Such additional queries may be triggered after a certain time, after a further detected pattern or after a further use of themonitoring apparatus 7000.
  • For example, when monitoring a heart failure patient for imminent acute decompensated heart failure (ADHF) events or a COPD patient for exacerbations, it may be desirable to query the patient to qualify a pattern detection made by theprocessor 7006. Such queries may serve to reduce false positives (e.g., when the processingflagsa need for clinical contact and the clinical contact is later found to have been unnecessary). This type of false positive may be due to changes in patient behavior, which may be corrected without medical intervention. Such behaviors may include missed or incorrect dosage of medication, non-compliance with dietary instructions and/or rest requirements, and the like.
  • For example, in some embodiments, in an effort to minimize false positives, the processor 7006may detect a respiratory pattern or potential clinical events that might require a clinical alert (e.g., a certain number of SDB events over a certain period of time that may be indicative of COPD exacerbation and/or ADHF). Based on the detected pattern or events, the processor 7006may present one or more questions in a queryto the patient on a user interface of theapparatus 7000. Such questions may address pharmaceutical and/or lifestyle compliance by the patient (e.g., has the patient been taking prescribed medication and/or following physician's treatment advice, etc.).Optionally, in some cases, one or more questions may address the operational integrity of themonitoring apparatus 7000 to ensure that the collected data is valid. Optionally, the processor 7006may pursue a series of queries over a predetermined span of time (such as one or more monitoring sessions or nights of sleep) and generate a clinical alert only after the predetermined span of time has elapsed.
  • For example, if a recurring respiratory pattern (such as one repeatedly detected in several monitoring sessions) indicates a likelihood of a clinical event, the processor 7006may prompt a series of queries to the patient regarding diet that might have a causal relationship with the recurring pattern. If the patient is not in compliance with the dietary requirements as determined by the patient's responses input to themonitoring apparatus 7000, the processor 7006may then continue to monitor and query the patient again after a further monitoring time period has elapsed (e.g., query the patient after a number of minutes, hours, or days). If the processor 7006detects a continuation of the detected respiratory pattern and the patient's responses indicate that diet is not a cause (e.g., the patient responds to a subsequent query that he or she is now in compliance with the dietary requirements), the processor 7006may then trigger a clinical alert message to a clinician via a notification infrastructure (e.g., tele-monitoring) to notify a clinician directly as described below. In some cases, a certain received response(s) to one or more questions of the query may alternatively rule out the triggering of such an alert message. For example, a query and response may determine that the patient was not wearing his or her mask and as a result, the processor 7006may refrain from triggering an alert.
  • The technology described above may be further illustrated with the following example.A heart failure patient does not take the prescribed diuretics for a period of time. Due to noncompliance, the patient experiences dyspnea and breathing irregularities at night. The processor 7006of themonitoring apparatus 7000 may detect such events, or a pattern of such events, which may be indicative of an imminent decompensation or exacerbation event. Instead of directly issuing a clinical alert to the clinician, themonitoring apparatus 7000 may trigger a query to the patient (e.g., via display device 7015) to determine whether the patient has taken the prescribed diuretics. The evaluation of the response may trigger a message to the patient, rather than an alert to a clinician, to remind the patient to take the medication if the input answer is negative. After a period of time, such as twenty-four hours, the processor 7006of themonitoring apparatus 7000 may then further evaluate the breathing patterns of the patient to see if the pattern recurs or has been resolved (by taking of the diuretics). An alert message would not be generated if the processor 7006does not detect the previously detected respiratory pattern that triggered the initial query. Optionally, the processor 7006may also confirm by a supplemental query that the patient has taken the medication. In such cases, monitoring may resume as usual thereafter. If, however, the recurring pattern is still or again detected by the processor after the initial query, a subsequent query, such as one with different questions, may be presented to the patient on thedisplay device 7015. After the predetermined number and frequency of queries have been performed, and the pattern is still detected by theprocessor 7006, themonitoring apparatus 7000 may then trigger an alert message to notify the clinician of an imminent clinical event. In this manner, the processor may be configured to dispose of simple cases of non-compliance (such as dietary or exercise) or explain apparatus malfunctions due to, for example, unintentional disconnections or power loss, without the need for a clinical alert message requesting that the patient be contacted.
  • In one example, the processor 7006may access thememory 7002 that includes a set of queries. Each question of a query may be associated with one or more detectable respiratory patterns or events. A question may be broad (e.g., "has patient complied with the prescribed diet?") or specific (e.g., "has patient diet been fortified with potassium?"). With the set of questions indexed by such detectable patterns or events, the processor 7006may then select a subset of questions for a query based on the detected pattern or event.
  • Questions may be presented in series in response to a particular monitoring session. For example, theprocessor 7006 may prompt two, three, four, five, six or more questions in a row so as to identify or rule out causes of the detected respiratory abnormality of the monitoring session that would or would not need an alert message. Alternatively, the processor 7006may access an associated rank or priority for the question that represents an order of likelihood. Thus, the processor 7006may conditionally present a series of questions according to the rank associated with each question. For example, the controller may present a first query in response to a predicted event. If in answering the first query, the patient response(s) indicates that the predicted event does not (at least yet) require an alert, the response and determination may be logged and theprocessor 7006 may proceed to a second monitoring session during a predetermined period of time. If the respiratory pattern is again detected, a second query of a different rank from the first query may then be triggered. This detection and querying cycle may be repeated until no further queries remain or a response to a query indicates a need for an alert, after which the processor 7006may then trigger an alert message.
  • Fig. 7b is a flow chart illustrating amethod 7100 of monitoring cardio-pulmonary health as implemented within themonitoring apparatus 7000 in one form of the present technology. Themethod 7100 is carried out by theprocessor 7006 of themonitoring apparatus 7000, configured by instructions stored on computer-readable storage medium such as thememory 7002.
  • At thefirst step 7110, the processor 7006monitorsand analyses data received from thesensor unit 1200 and any other sensors described aboveso as to predict whether a clinical event is likely to occur within a predetermined prediction horizon, as described in detail below. If atstep 7120 no event is predicted ("N"), the processor 7006may continue monitoring / analysis at 7110. If a potential clinical event is predicted at 7120 "Y"), theprocessor 7006at 7130 triggers generation of one or more queries to evaluate a potential cause of the clinical event,such as by displaying them ondisplay device 7015,as discussed in more detail herein,and/or on another processing device (e.g., tablet computer, mobile phone or other computing device etc.) in direct or indirect communication with theprocessor 7006. Depending on the patient input response to the query received atstep 7140, the processor 7006and/or such other processing devicemay proceed to step 7180 to trigger generation of a clinical alert immediately (shown as a dashed arrow 7145), or postpone the clinical alert generation by proceeding to step 7150.
  • Atstep 7150, the processor 7006may control adjustment of a treatment in response to the received responseto the patient queries. For example, the processor 7006may modify atarget ventilation, or other treatment control parameters of aPAP device 4000. Alternatively, the processor 7006may maintain the same treatment as that provided during the monitoring /analysis step 7110, and instead issue an instructional message to instruct the patient to make an adjustment, such as a change in diet or medication or a resetting or repair of theapparatus 7000 orPAP device 4000. At thenext step 7160, after a predetermined delay (e.g. 24 to 48 hours), the apparatus monitors and analyses the sensor datain similar fashion to step 7110 to determine whether the instructed or controlled adjustment ofstep 7150 resolved the issue previously detected atstep 7110 (e.g., by determining if the predicted clinical event is still predicted). If atstep 7170 the issue has been resolved (e.g., the clinical event is no longer predicted) ("Y"), themethod 7100 returns to step 7110 to continue monitoring and analysingsensor data. If the clinical event is still predicted ("N"), themethod 7100 may return to step 7130 or 7150 (via dashedarrows 7175 and 7178 respectively) if further queries or adjustments are available, or if not, generation of a clinical alert is triggered atstep 7180 as describedin more detail herein.
  • 9.5.2.3 Relapse monitoring
  • In some embodiments, themonitoring apparatus 7000 may be implemented with additional operations. For example, as previously mentioned, themonitoring apparatus 7000 may be useful to determine whether or not a hospitalized patient (e.g., a heart failure or COPD patient) is ready to be released or should not be released from the hospital. Releasing a patient too soon may not be beneficial for the patient, particularly if a relapse occurs shortly thereafter and the patient must be re-admitted. Heart failure and COPD patients suffer from decompensations and/or exacerbations and frequently require re-admission to a hospital due to relapse that might be avoided with a longer initial stay. Similarly, releasing a patient too soon may have consequences for other entities. For example, hospitals may not be reimbursed or may only be partially reimbursed for the costs associated for a re-admission as a result of such a relapse. Thus, it would be useful to provide techniques for predicting a likely relapse of a COPD or HF patient, as a tool for helping to avoid releasing a patient from the hospital too soon. Some forms of the present technology evaluate a patient's condition during a first time period to provide a prediction relating to the potential for relapse in a subsequent time period. For example, for heart failure and/or COPD patients, the potential for post-hospitalization decompensation and/or exacerbation events may be predicted from an analysis of respiratory parameters during hospitalization, such as an analysis of the respiratory movement signalsas previously described.
  • Accordingly, amonitoring apparatus 7000 may be configured to monitor and analyse respiratory parameters during a time period from admittance to discharge that may be indicative of a likelihood of post-discharge relapse. By monitoring and analysing the respiratory parameters within the period from admittance to a point near or prior to discharge, themonitoring apparatus 7000 may determine whether the patient might be at risk for re-admission soon after release. In this regard, the methodology of themonitoring apparatus 7000 can provide a potential relapse alert to a clinicianto advise whether release might be premature due to a risk of relapse. For example, themonitoring apparatus 7000 might warn the clinician that once released, the patient might be at a high risk for relapse and/or readmission and may further advise that careful monitoring for relapse should be considered for the particular patient or that the release should be reconsidered or postponed. In some cases, such a potential relapse alert may be presented as a numerical value, such as a Booleanindicator or a probability, which may comprise an estimate within a range so as to yield a scaled indication of greater or lesser risk of future relapse.
  • Fig. 7c is a flow chart illustrating a method of monitoring the cardio-pulmonary health of a patient as implemented within themonitoring apparatus 7000 in one form of the present technology. Themethod 7200, which may be used with a patient while the patient is hospitalized, is carried out by theprocessor 7006 of themonitoring apparatus 7000 and/or a processor in direct or indirect communication with such processor, configured by instructions stored on computer-readable storage medium such as thememory 7002.
  • Themethod 7200 at thefirst step 7210 extracts, monitors, and records respiratory parameters of a patient over the admission period, including one or more of the breathingrate, minute ventilation, tidal volume, sleep-disordered breathing severity indicators(e.g., apnea / hypopnea index), inspiratory waveform shape, expiratory waveform shape and the like,from data obtained with any one or more of the previously mentioned sensors. Themethod 7200 may perform an analysis of one or more of the extracted respiratory parameters to calculate an indicator of potential relapse or a probability of relapse atstep 7220.Step 7220 may involve assessing how the parameters have changed during the course of the hospitalization period. One or more of the parameters or the changes therein may be compared to one or more thresholds in order to compute an indicator of potential relapse. Such thresholds may be empirically determined from historic data of one or more hospitalized patients who have relapsed and/or not relapsed after hospitalization. Optionally, such data may be based on thresholds taken from historic data of the particular patient. Alternatively, or additionally, a probability of relapse may be calculated atstep 7220 based on a pattern of a plurality of the parameters or changes in a plurality of parameters. Such comparisons and/or pattern evaluations may be made, for example, by a decision-tree, a classifier or any other method of evaluation. Based on the computed probabilityof relapse or potential relapse indicator, a potential relapse alert may be generated atstep 7230. For example, data indicative of the probability of relapse, such as the potential relapse indicator or the calculated probability of potential relapse, may be displayed ondisplay device 7015 and/or sent as a message to a clinician via theconnection 7008 atstep 7230.
  • In some embodiments, the potential relapse indicator or probability of relapse may be continuously updated and displayed or transmitted based on a continuous monitoring and analysis of the extracted respiratory parameters during the monitoring period of hospitalization. However, in some embodiments, the indicator, probability and/or message concerning the potential for relapse may be generated in response to a request made by a user, such as a clinician, either through a user interface of the apparatus 7000 (e.g., one or more buttons or operation of a user interface of the apparatus) or by transmitting an electronic request to initiate themethod 7200. In this regard, themonitoring apparatus 7000 may be configured to generate the potential relapse alert based on its previous analysis of the respiratory parameters. However, in some embodiments, the respiratory parameters used in themethod 7200 may be extracted by and transmitted from themonitoring apparatus 7000 to theexternal computing device 7005, which may implement the steps 7220and 7230 that calculate the probability of potential relapse or relapse indicator from the received respiratory parameters, and generate the potential relapse alert.
  • 9.5.2.4 Event prediction
  • Fig. 7d is a flow chart illustrating the principal steps in amethod 7300 of predicting clinical events from signals representing movement (movement signals). Themethod 7300 may be used to implementstep 7110 of themethod 7100 in one form of the present technology in which the sensor data are one or more movement signals obtained from themotion sensor 7010, and the features related to cardio-pulmonary health are one or more SDB features. Themethod 7300 may also be used to implementsteps 7210 and 7220 of themethod 7200 in one form of the present technology in which the sensor data are one or more movement signals obtained from themotion sensor 7010, and the respiratory parameters are one or more SDB features. In one implementation, themethod 7300 is carried out by theprocessor 7006 of themonitoring apparatus 7000, configured by instructions stored on computer-readable storage medium such as thememory 7002, and the movement signals are obtained from thecontactless motion sensor 7010.
  • Themethod 7300 starts atstep 7310, at which the movement signals are pre-processed to condition them for further processing. The pre-processing step 7310 (shown dashed inFig. 7d) is optional and may be omitted. At thenext step 7320, the pre-processed movement signals are analysed to extract SDBfeatures indicative of the severity of SDB by thepatient 1000 during the period represented by the movement signals. Finally at aprediction step 7330, themethod 7300 uses the extracted SDBfeatures to predict whether a clinical event is likely to occur within the predetermined prediction horizon.
  • As described above, in one form of the present technology thecontactless motion sensor 7010 is a Doppler RF motion sensor. In such an implementation, the motion sensor7010 provides two raw movement signals, labelled I and Q signals 7003a and 7003b, each generally indicative of bodily movement, but generally 90 degrees out of phase with each other.
  • In a firstor "parallel" approach, thesteps 7310 and 7320 are performed on each of the I and Q signals 7003a and 7003bin parallel, and the separately obtained features are combined during thefeature extraction step 7320. In one implementation, under the "parallel" approach, thepre-processing step 7310 may be omitted. In a second or "combined" approach, the I and Q signals 7003a and 7003bare combined as part of thepre-processing step 7310, and theprocessing steps 7320 to 7330 are carried out on the combined movement signal. The combined approach has the advantage of less computational complexity than the parallel approach, at the potential cost of lower prediction accuracy.
  • In other forms of the present technology, thecontactless motion sensor 7010 provides asingle movement signal 7003. This is referred to below as the "single-channel" approach.
  • In one form of the present technology,step 7330 is omitted, i.e. no prediction of clinical events is made. The SDB features extracted atstep 7320 may be used to trigger clinical alerts as described above. Alternatively, the extracted SDB features may be stored in thememory 7002 or transmitted to theexternal computing device 7005 for later diagnostic review.
  • The following sections describe implementations of each of thesteps 7310 to 7330 of theevent prediction method 7300 in more detail.
  • 9.5.2.4.1Pre-processing 7310
  • Under the "combined" approach,thepre-processing step 7310 begins by combining the land Q signals 7003a and 7003b in an adaptive geometrical manner into a combined movement signal c. In one implementation, the combination sub-step comprises three stages, applied to a window that slides along the I and Q signals 7003a and 7003b. In one implementation, the window is of 10 seconds duration with 50% overlap.
    1. a. Check if the signals are 180 degrees out of phase using a cross-correlation, and flip them back to the same quadrant if so.
    2. b. As the vectors (I,Q) form a cloud of points around a quasi-circular arc, subtract the mean of the cloud to centre the arcat (0, 0), locate the minimummIQ of the centred cloud of points in both directions, and compute the lengthm of each vector (I,Q) referred tomIQ.mIQ=mImQ=minII,minQQ
      Figure imgb0004
      m=ImI2+QmQ2
      Figure imgb0005
    3. c. Subtract the mean ofm to produce the (one dimensional) combined signalc.c=mm
      Figure imgb0006
  • The combined movement signalc is then (optionally) de-trended to remove baseline wandering. In one implementation, de-trending is implemented using a third-order polynomial:c1=DTpoly,3c
    Figure imgb0007
  • In another implementation, de-trending is implemented using double-pass median filtering.
  • The de-trended signalc1 is (optionally) bandpass filtered with a Butterworth bandpass filter with range set to the frequency range of respiratory functioning, this being in one implementation [0.1 Hz, 0.8 Hz] (corresponding to 6 to 48 breaths per minute).
  • A further (optional) sub-stepin thepre-processing step 7310 is noise reduction. In one implementation, particularly suited to signals from DopplerRF motion sensors 7010, which are non-stationary, the noise reduction sub-stepis carried out in the wavelet transform domain on the (bandpass filtered) de-trended combined movement signalc2:c3=W1MWc2
    Figure imgb0008

    whereW represents a wavelet transform, for example the 30-coefficient "symmlet" wavelet up to the fifth dyadic level, andM is a masking matrix that passes certain wavelet coefficients and rejects other considered as "perturbative".
  • The steps to implement the action ofM are as follows:
    1. a. Select the dyadic scales for which the "artefactness" (see below) of the wavelet coefficients is above a first thresholdTA;
    2. b. From this set of scales, perform a hard thresholding (with thresholdTC) of the wavelet coefficients based on the standard deviation.
  • The "artefactness" at a scale quantifies the degree to which an artefact affects the signal at that scale. Artefactness is a measure of the skewness of the signal which can contain unlikely high amplitude values. The artefactness of a signalxmay be computed as:Artx=2σxmaxxminx
    Figure imgb0009

    whereσx is the standard deviation of the signal x. The furtherArt(x) is from 1, the larger the artefact is.
  • Under the "parallel" approach mentioned above, the combinationsub-step is omitted from thepre-processing step 7310, and any or all of the subsequent sub-steps (de-trending, filtering, and noise reduction) are performed in parallel on each of the I and Q signals 7003a and 7003b.
  • Under the "single-channel" approach, any or all of the de-trending, filtering, and noise reduction sub-steps are performed on themovement signal 7003.
  • In the description below, the input(s) to thefeature extraction step 7320 is / are referred to as (pre-processed) movement signal(s) to reflect the optional nature of thepre-processing step 7310.
  • 9.5.2.4.2Feature extraction 7320
  • Fig. 7e is a block diagram 7400 illustrating the modules making up one implementation of thefeature extraction step 7320 and their relationship under the combined or single-channel approach
  • In the implementation illustrated inFig. 7e, an activity estimation andmovement detection module 7410 generates an activity count signal and a movement flag series from the (pre-processed) movement signal. A presence /absence detection module 7420 generates a presence / absence flag series from the (pre-processed) movement signal and the movement flag series. A sleep /wake analysis module 7430 calculates a hypnogram from the presence / absence flag series, the movement flag series, and the activity count signal. A breathingrate estimation module 7440 generates a series of estimates of the breathing rate of the patient from the (pre-processed) movement signal and the hypnogram. Asignal selection module 7450 selects sections of the (pre-processed) movement signal, using the movement flag series and the hypnogram. A modulation cyclemetrics calculation module 7455 generates an estimate of the modulation cycle length of the patient's respiration from the selected sections of the (pre-processed) movement signal. Anenvelope generation module 7460 generates envelopes of the selected sections of the (pre-processed) movement signal using the estimated breathing rate. An SDBevent detection module 7465 generates candidate SDB events from the selected sections of the (pre-processed) movement signalusing the estimated modulation cycle length. An SDBevent confirmation module 7470 confirms the candidate SDB events generated by the SDBevent detection module 7465. Finally, afeature calculation module 7580 calculates SDBfeature values from the confirmed SDB events.
  • Under the parallel approach, themodules 7410 to 7470 of the block diagram 7400 are simply duplicated to process each of the I and Q signals 7003a and 7003b independently. A modified version of thefeature calculation module 7480 combines the SDB events from the two parallel processing streams to calculating a single SDB feature set for the two (pre-processed) movement signals.
  • Under a "hybrid" approach, certain modules of thefeature extraction step 7320 are duplicatedso as to process the (pre-processed) movement signals independently, and the intermediate results are combined within various modules of thefeature extraction step 7320 as described below.
  • Fig. 7f is a block diagram 7500 illustrating the modules making up one implementation of thefeature extraction step 7320 and their relationship under the hybrid approach.
  • In the implementation illustrated inFig. 7f, an activity estimation andmovement detection module 7510 generates an activity count signal and a movement flag series from the I and Q signals 7003a and 7003b. A presence /absence detection module 7520 generates a presence / absence flag series from the I and Q signals 7003a and 7003b and the movement flag series. A sleep /wake analysis module 7530 calculates a hypnogram from the presence / absence flag series, the movement flag series, and the activity count signal. A breathingrate estimation module 7540 generates a series of estimates of the breathing rate of the patient from the I and Q signals 7003a and 7003b and the hypnogram.Signal selection modules 7550a and 7550b select sections of the I and Q signals 7003a and 7003b respectively, using the movement flag series and the hypnogram. A modulation cyclemetrics calculation module 7555 generates an estimate of the modulation cycle length of the patient's respiration from the selected sections of the I and Q signals 7003a and 7003b.Envelope generation modules 7560a and 7560b generate envelopes of the selected sections of the I and Q signals 7003a and 7003b respectively using the estimated breathing rate. SDBevent detection modules 7565a and 7565b generate candidate SDB events from the selected sections of the I and Q signals 7003a and 7003b respectively using the estimated the modulation cycle length. SDBevent confirmation modules 7570a and 7570b confirm the candidate SDB events generated by the SDBevent detection modules 7565a and 7565b respectively. Finally, a feature calculation-module 7580 calculates SDBfeature values from the confirmed SDB events.
  • Each of the modules making up thefeature extraction step 7320 is described in detail in the following sections.
  • 9.5.2.4.2.1 Activity estimation and movement detection7410
  • The activity estimation and movement detection moduleretums a time series of "activity count" valuesindicating the level of bodily activity and a time series of binary movement flags indicating the presence or absence of gross bodily (non-respiratory)movement. Each time series is sampled at the sampling rate of the (pre-processed) movement signals (the movement signal frequency), equal to 10 Hz in one implementation. The movement flag series is used by the presence / absence detection, sleep / wake analysis, signal selection, and breathing rate estimation modules described below. In particular, the signal selection module selects for analysis those sections of signal that are not dominated by gross bodily movement. The activity count series, as well as the duration of movements and the time elapsed from the previous movement,is used by the sleep / wake analysis module to determine the sleep/wake state of the patient.
  • In one implementation, the activity estimation and movement detection moduleis based on movement signal power levels, movement signal morphology, and movement patterns.
  • In one implementation, five main sub-modules form part of the activity estimation and movement detectionmodule.
  • An activity mappingsub-module generates a series of activity count values which are generally proportional to the power of the movement signal at corresponding times. The activity count is generated in the following manner:
    • The signal is bandpass filtered to the range [1.5 Hz, 4.5 Hz].
    • A maximum filter ofduration 4 seconds is run over the signal to obtain an amplitude envelope.
    • The baseline of the signal (due to residual respiration activity) is extracted by estimating the 5th percentile of the signal on rolling 20-second windows.
    • The difference between the envelope and the baseline is compared to a threshold (0.0075V in one implementation) and scaled again by the envelope.
    • The signal is partitioned into non-overlapping intervals. In one implementation, each interval is of duration two seconds.
    • The scaled signal is integrated over each interval and up-sampled to the movement signal frequency to produce the activity count series.
  • In one implementation, amovement detector sub-module proceeds as follows.
  • The signal is first highpass filtered to remove VLF components and baseline. Three features are then derived from the baseline-removedsignal. The first feature is referred to as a noise feature.
    • A highpass filter with cutoff frequency around 1 Hz is applied to remove respiration components.
    • The highpass filtered signal is then partitioned into non-overlapping intervals. In one implementation, each interval is of duration two seconds.
    • The noise feature is calculated as the root mean square(RMS) of the filtered "noise" signal for each interval.
  • The second and third features are correlation and power features and are computed on a different frequency band to the noise feature.
  • The mean breathing rate of the overall monitoring session is first estimated by running an unbiased autocorrelation of the baseline-removed signal and finding the first minimum, which defines half the mean breathing rate. The mean breathing rate defines a patient-specific acceptable breathing rate frequency window as a range of frequencies around the mean breathing rate.
  • A lowpass filter ,with cutoff around 2 Hz in one implementation, is applied to the baseline-removed signal. The lowpass filtered signal is then partitioned into overlapping windows, de-trended and de-meaned. In one implementation, the windows are 15seconds long with 12 seconds of overlap (three seconds of shift).
  • The correlation feature is calculated by:
    • Taking the unbiased autocorrelation of the de-trended and de-meanedsignal in each window.
    • Selecting the first peak, provided it is within the patient-specific acceptable breathing rate window defined by the mean breathing rate. (In the negative case, the correlation feature is set to 0.)
  • The power feature may be calculated by:
    • Calculating the power spectral density of the lowpass filtered signal for each window.
    • Identifying the maximum within the patient-specific acceptable breathing rate window as defined from the mean breathing rate.
    • Selecting a breathing band of +/-0.05Hz over the maximum frequency and the first two harmonics.
    • Calculating the ratio between the signal power in the selected breathing band and that in the full band of the signal.
  • As the window length is greater than the three-second shift between windows, a maximum filter may be run over the correlation and power features so calculated.
  • All three features may bethen interpolated to the movement signal frequency so that a feature value is present for each sample in the (pre-processed) movement signal.
  • The noise feature may be normalized by the mean power feature calculated for all samples with high correlation feature values (those with values greater than 0.9) and those with high power feature values (those with values greater than 0.8).
  • The baseline of the noise feature may be calculated by assigning to noise feature values over 0.003the 95th percentile of all values below 0.003. Then a median filter of width 180seconds is run and the baseline is defined as the 50th percentile of the filtered series. This baseline is then subtracted from the noise feature.
  • If the baseline-removed noise feature is above a "high" threshold (equal to 1 in one implementation) and the correlation and power features are below a "low" threshold (equal to 0.7 in one implementation), the corresponding movement flag is set to true. If the baseline removed noise feature is above its mean value, the movement flag is also set to true.
  • The movement flag series is finally expanded before and after each detected movement section by running the movement flag series through a maximum filter of multi-second duration, equal to 4 seconds in one implementation.
  • The movement correction sub-module produces a binary "validation" flag for the movements detected in the movement detector sub-module, by analysing trends of movement over several minutes. Movements associated with apneas, in fact, need not to be labelle das such as it would impair the performance of both the sleep/wake analysis and SDB event detection modules.
    • A repetitive movement mask is obtained by merging all movements within 120seconds of each other, to identify sections where trains of apneas (generally obstructive) might be falsely labelled as movement sections and subsequently labelle das wake.
    • Only sections with duration of at least 5 minutes are processed by this sub-module, with 2/3 overlapping (implemented by partitioning into 300-secondwindows with 100-second shifts between them).
    • An amplitude envelope may begenerated by:
      • ∘ Performing peak-trough detection in the same manner as in the breathing rate estimation moduledescribed below.
      • ∘ Defining an individual breath's start and end point as the mid-point between one peak and its successive trough.
      • ∘ Assigning the envelope the peak-to-peak amplitude of the signal during each detected breath
    • The amplitude envelope may befiltered with a lowpassfilter with cutoff 0.5 Hz.
    • The filtered envelope ismay be smoothed by performing soft-limiting when it exceeds its 70th percentile value or twice its standard deviation and by hard-limiting it once it reaches its 70th percentile multiplied by a scaling factor of 1.6.
    • The autocorrelation of the envelope may be calculated for the interval, and the first two peaks and troughs in the autocorrelation function corresponding to periods between 16seconds and 90seconds are identified.
  • The difference between the value of each peak and its preceding trough may be calculated and, if found to be greater than a set threshold, the whole interval is marked as non-movement, as a repetitive pattern compatible with a train of SDB events is deemed to be likely.
  • Under the hybrid approach, there follows a combination sub-module, in which:
    • Activity counts across both (pre-processed) movement signals are averaged.
    • Movement flags across both (pre-processed) movement signals are combined through an AND operation (that is, movement needs to have been detected on both signals to generate a true movement flag.)
  • Under the other approaches, the combination sub-module is not needed.
  • The final sub-module calculates movement state duration. This sub-module identifies all movement / no-movement transitions and generates a vector with the duration of all individual movement/no movement states.
  • The mean non-zero activity count, together with its standard deviation, skewness, kurtosis, and the 5th, 25th, 50th, 75th and 95th percentile of the distribution over all intervals with non-zero activity counts,mayalso calculated and stored. The total duration of intervals with non-zero activity counts may be calculated and stored as the Total Movement Time. The percentage of intervals with non-zero activity counts during the monitoring sessionmayalso be calculated and stored. This percentage may also becalculated on those periods that are marked as the first and second halvesof the main sleep period (defined below).
  • 9.5.2.4.2.2 Presence /Absence detection 7420
  • The presence / absence detection module detects whether the patient is present within the field of the sensor 7010 (i.e. in bed), or is absent (i.e. not in bed). The presence/absence detection module generates a time series of presence / absence flagsbased on signal power levels, signal morphology, and the movement flag series generated by the activity estimation and movement detection module.
  • In one implementation, the presence / absence detection modulemay include sub modules. For example, five main sub-modules may be implemented as follows:
    • Pre-processing, performed separately on each (pre-processed) movement signal, in which, for example:
      • ∘ The signal is highpass filtered with cutoff 0.1 Hz to remove baseline wander and low frequency components that might affect the morphological feature.
      • ∘ The signal is split into non-overlapping epochs for analysis. Epoch length is chosen to be long compared to the duration of a breath. In one implementation, each epoch is 30 seconds in duration.
      • ∘ The signal is de-meaned over each epoch.
    • Amplitude Analysis - Morphological Feature Gate,may also be performed separately on each (pre-processed)movement signal after the pre-processing sub-module.This sub-modulemay, for example, verify that:
      • ∘ The RMS value of the signal in each epoch is greater than a minimum value associated with certain absence (equal to0.0015 in one implementation).
      • o The signal in each epoch does not contain clear outliers. The assumption is that, in the case of low amplitude signal, there will be either quasi-Gaussian noise or small amplitude breathing. Outliers are deemed to be present if the ratio between either the 99.95th and the 66.6th or the 33.3rd and the 0.05th percentile exceeds a factor of 6. For a Gaussian distribution this ratio should not exceed 3: a safety factor of 2 is employed.
      • ∘ If both the above conditions are verified, the morphology feature calculated by the next sub-module as described below is kept intact.
      • ∘ If the first condition is not verified (the assumption is absence), the morphology feature is set to the maximum of its calculated value and a value that is large enough to guarantee absence being detected.
      • ∘ If the second condition is not verified, the morphology feature is assigned a NaN(not a number) value, and the epoch will be ignored in the detection of presence and absence (the assumption is burst of noise or twitch).
    • Calculation of Morphology feature,also may be performed separately on each (pre-processed)movement signal after the pre-processing sub-module and may be implemented as follows:
      • o The morphology feature is calculated as the kurtosis of the autocorrelation of the signal during the epoch. An uncorrelated signal will return a peaky autocorrelation function, whereas a breathing signal will return an autocorrelation function with periodic peaks. Kurtosis is larger for a peaky distribution. A larger value of the morphology feature is associated with absence.
    • Artefact removal, trending, and combination.This sub-modulemay be performed on the, or each,morphology feature series calculated by the previous sub-module as follows:
      • ∘ Isolated high values of the morphology feature are assigned the value of the previous epoch.
      • ∘ For each signal, a mean filter, set to nine epochs in length in one implementation, is run over the morphology feature series.
      • ∘ Under the hybrid approach, a temporary combined feature vector is generated as follows. In case the RMS of both signals falls below a maximum threshold associated with expected presence (set to 0.01 in one implementation), the vector is assigned a value equal to the mean of the morphology feature of each input signal, otherwise a value of zerois assigned to skew the presence / absence flag towards presence.
      • ∘ The (combined)morphology feature series is converted to a presence / absence flag series by comparing each value with an absence/presence threshold, setto 20 in one implementation. If a morphology value is less than the threshold, the corresponding flag is set to True (presence); otherwise, the flag is set to False (absence).
    • Post-processing, performed on the presence / absence flag series, may be implemented making use of the movement flag series generated by the activity estimation and movement detection module as follows:
      • ∘ Transitions upon power up of themonitoring apparatus 7000 are ignored by assigning the flag value of the 5th epoch to the initial four.
      • ∘ All the transitions from presence to absence and from absence to presence are examined. If during the section between the last movement(indicated by the movement flag series) prior to the presence/absence transition and the transition itself at least 85% of the morphology feature values are not NaN, the transition is moved back to the epoch following the previous movement. The equivalent is done for transitions between absence and presence. (The rationale for this type of re-labelling is that a presence/absence transition should be associated with a gross bodily movement into /out of bed.)
  • In an alternative implementation of the presence / absence detection module, suitable for the combined or single-channel approaches, for each epoch, the presence / absence flag is set to False (absence) if the RMS value of the (pre-processed) movement signal within the epoch falls below a "noise-only" threshold, set to 0.015 in one version of the alternative implementation in which the epochs are of 5-second duration. Otherwise, the presence / absence flag for the epoch is set to True (presence). The alternative implementation does not use the movement flag series.
  • 9.5.2.4.2.3 Sleep /wake analysis 7430
  • The sleep/ wake analysis module aims to classify each epoch as asleep, awake, absent, or unknown. (The epochscoincide with the epochs of the presence / absence detection module.) The resulting series of epoch classifications is referred to as a hypnogram.
  • In one implementation, the sleep / wake analysis module uses the activity estimation and movement detection module outputs to generate features which are fed into a classifier for each epoch. Some initial post-processing, integration with the presence/absence flags from the presence/absence detection module,and final post-processing allows the sleep / wake analysis module to refine the hypnogram.
  • In this implementation, the sleep/ wake analysis module may be implemented with a number of sub-modules (e.g., four) as follows.
  • A feature extraction sub-module extracts some or all of the following features from the activity count signal and movement flag series:
    • Activity feature, which may be processed as follows:
      • ∘ The activity countsignalis normalised by dividing it by its mean, to reduce the range/sensitivity effect.
      • ∘ The normalised activity count signal is integrated over each epoch.
      • ∘ The fourth root of the integral is computed.
    • Duration of movement feature, which may be processed as follows:
      • ∘ For each epoch, if one or more portions of movement are present, the square root of their mean duration in samples (including portions outside of the epoch of interest) is computed.
    • Duration of no movement feature,which may be processed as follows:
      • ∘ For each epoch, if one or more portions of no movement are present, the square root of their mean duration in samples (including portions outside of the epoch of interest) is computed.
    • Kushida activity feature,which may be processed as follows:
      • ∘ The Kushidaactivity is a weighted summation applied to the integrated activity counts, with weights set in one implementation to {0.04, 0.04, 0.2, 0.2, 2, 0.2, 0.04, 0.04} / 2.96. (The Kushida activity feature for the initial four and final four epochs are only based on partial weighted sums.)
  • A classifier sub-module classifies the extracted features in each epoch to generate provisional sleep/wake labels [Sleep = 0, Wake =1]. In one implementation, the classifier is a pre-trained linear discriminant analysis (LDA) classifier.
  • A post-processing sub-module may process the provisional sleep / wake labelseries in the following fashion:
    • The provisional sleep / wake labels are post-processed in accordance with Lotjonen pattern expansion, where short burst of Wake or Sleep within a larger Sleep or Wake section are relabelled as Sleep and Wake respectively. Lotjonen pattern expansion is illustrated inFig. 7g.
    • Presence / absence flags from the presence/absence detector module are overlaid on the post-processed sleep / wake labelseries. A first temporary hypnogram is generated from the post-processed sleep / wake label series by assigning a NaN value to each epoch labelled as Sleep that coincides with an epoch flagged as Absent.
    • Meanwhile, the raw (un-post-processed) provisional sleep / wake labels are overwritten with Wake labels where NaN values are present in the first temporary hypnogram,and post-processed using the Lotjonen pattern expansion method to generate a second temporary hypnogram.
    • The second temporary hypnogram is combined with the first temporary hypnogram as follows: at each epoch where the first temporary hypnogram value is Sleep and the second temporary hypnogram value is Wake,the first temporary hypnogram value is set to Unknown.
  • The first temporary hypnogram becomes the final hypnogram after the following final post-processing steps:
    • Where an Unknown label is between two Wake labels, it is set to Wake.
    • Where at least 15 minutes of consecutive Unknown labels are present, those labels are set toAbsent.
    • Sections of non-absence of duration less than or equal to 5 minutes are relabelled as Absent.
    • Finally,any Wake present at the beginning and/or end of the raw (un-post-processed) hypnogram is maintained in the final hypnogram.
  • In an alternative implementation, suitable for the combined or single-channel approaches, the sleep / wake analysis module uses the presence / absence flag series from the presence / absence detection module and the combined (pre-processed) movement signal to generate the hypnogram labelling each epoch as Sleep, Wake, or Absent. In the alternative implementation, the sleep / wake analysismodule does not use the movement flag series generated by the activity estimation and movement detection module, but rather generates its own movement flag series (one flag for each epoch, indicating gross bodily movement within the epoch) by comparing the variance of the movement signal within the epoch with an adaptive threshold for the monitoring session. The adaptive threshold may, for example, beset in one version of the alternative implementation to the 95th percentile of the variance over the monitoring session minus twice the 75th percentile of the variance over the same monitoring session (when the 75th percentile is bigger than 0.5), or to the 95th percentile of the variance over the monitoring session minus 1.5 times the 75th percentile of the variance over the monitoring session (when the 75th percentile is less or equal to 0.5). If the variance exceeds the adaptive threshold, the movement flag for the epoch is set to True.
  • In the alternative implementation, the epochs labelled as Absent in the presence / absence flag series are first labelled as Absent in the hypnogram. A "waveform length" feature is extracted from the (pre-processed) movement signalc3 within each epoch labelled as Present in the presence / absence flag series. Waveform length is calculated by measuring the cumulative changes in amplitude from sample to sample over the epoch. Metaphorically, it is the equivalent of treating the movement signal waveform like a jumbled string, and measuring the straightened-out length of the string. The waveform length feature effectively encapsulates the amplitude, frequency, and duration of the movement signal over the epoch. The waveform length feature valuewifor epochiis calculated as
    Figure imgb0010
    whereN is the number of samples in the epoch.
  • The waveform length feature valuewi for each Present epochi is compared with an adaptive thresholdT. If the valuewi is less than the thresholdT, the Present epoch is labelled as Sleep in the hypnogram; otherwise, the Present epoch is labelled as Wake.In order to compute the threshold valueT for the monitoring session, the inter-quartile range features are calculated for the waveform length featurewi over the monitoring session (with each point in this feature vector representing the waveform length of an epoch,in similar fashion to the well-known R&K sleep scoring criteria). The thresholdTis computed from the 50th, 75th, and 95th percentilesw50,w75, andw95 of the waveform length featurewiusing the method illustrated in the flow chart ofFig. 7h. The parametersα1,α2,β1,β2, andβ3 are set to 4, 2.78, 10, 0.95, and 4 in one version of the alternative implementation.
  • A summary sub-module may calculate any of the following summary metrics from the final hypnogram:
    • total sleep time (TST)(the sum of the durations of all epochs labelled as Sleep).
    • the total time in bed (the sum of the durations of all epochs not labelled as Absent).
    • sleepefficiency(the ratio of total sleep time to total time in bed between the first and last epochslabelled as Asleep).
    • thesum of the durations of epochs labelled as Unknown (if any).
  • The hypnogram might indicate multiple separate contiguous sections where the patient is present (i.e. marked as Sleep or Wake). This is especially true for patients who are spending part of the daytime in bed because of their condition. The summary sub-moduletherefore generates "temporary sleep periods" by locating contiguous sections marked as Sleep or Wake, ignoring Absent-marked sections that are shorter than a threshold, set in one implementation to 30 minutes. For example, from five sections with the patient present during the monitoring session, two "temporary sleep periods" might be generated, because three of the four Absent-marked gaps between the presence sections are shorter than the threshold. The summary sub-modulethen defines a "main sleep period" as the longest of the "temporary sleep periods" so generated, and marks the start and end of the first and second halves of the main sleep period.
  • 9.5.2.4.2.4Breathing rate estimation 7440
  • The breathing rate estimation module makes an offline non-causal estimation of the breathing rate for each epoch of the monitoring session, using a breath detector based on peak-trough detection of the (pre-processed) movement signals. (The epochs coincide with the epochs of the presence / absence detection module and the sleep / wake analysis module.) The output of the breathing rate estimation module is referred to as a respirogram.
  • In one implementation, four main sub-modules may serve as a breathing rate estimation module:
    • A pre-processing sub-module mayimplement any of the following steps:
      • ∘ Blanking out the sections of the movement signal that coincide with movement flags.
      • ∘ The signal may be filtered with a lowpass filter to remove any residual undetected movement. In one implementation, the lowpass filter is a Butterworth filter oforder 10, with a cutoff frequency of 0.8 Hz.
    • A peak-trough detectionsub-module may implement any of the following steps:
      • ∘ The signal is passed through a highpass filter to remove the VLF components. In one implementation, the cutoff frequency is 0.15 Hz.
      • ∘ The average breathing rate across the monitoring session is estimated by performing autocorrelation over the whole filtered signal and selecting the first peak after 0.5 Hz.This average breathing rate is scaled up by a factor of 1/0.8 for further processing, to ensure all breaths will be captured.
      • ∘ A Rayleigh distribution is built with its peak at half of the average breathing duration. This distribution will be used as a likelihood factor for identifying turning points (hence only half of the breathing duration is used).
      • ∘ All turning points on the filtered signal are identified.For each turning point:
        • ∘ Select all turning points over the next 10 seconds as candidate turning points.
        • ∘ Define a figure of merit as the distancefrom the current turning point to the candidate turning point, multiplied by its own Rayleigh probability (the Rayleigh distribution value at the distance from the current turning point).
        • ∘ The turning point with the highest figure of merit is chosen and the process is repeated going forward.
        • ∘ Remove all turning points associated with previously detected movement sections.
    • A breathing rate estimation sub-module proceeds as may implement any of the following:
      • ∘ From the turning points identified by the peak-trough detection sub-module, troughs are discarded, so that only peaks are considered.
      • ∘ Respiration intervals are defined as the distance between successive peaks. Respiration intervals greater than or equal to a duration that is long compared to a typical breath interval, set in one implementation to 7 seconds, are removed, as these are likely to be associated with interruptions in breathing or with movements.
      • ∘ The breathing rate for a window surrounding each epoch is computed as the median breathing rate (reciprocal of respiration interval) over all breaths in the window. In one implementation, the window is 3.5 minutes long.
    • Under the hybrid approach, there follows a combination sub-module, in which breathing rates from both (pre-processed) movement signals are averaged at each epoch. Under the other approaches, the combination sub-module is not needed.
  • Given the length of the window used for breathing rate estimation, the breathing rate estimation module includes a fair amount of averaging and is therefore fairly robust against artefacts. However, for the same reasons, it is not very sensitive to local breathing rate variations.
  • For all epochslabelled in the hypnogram as Absent or Unknown, the breathing rate is assigned a NaN value.
  • In an alternative implementation, the breathing rate estimate is simply the valueFreq computed using (Eq. 19) by the activity estimation and movement detection sub-module.
  • The mean breathing rate over the monitoring session, together with its standard deviation and the 5th, 25th, 50th, 75th and 95th percentile of the distribution, are mayalso be calculated and stored by the breathing rate estimation module.
  • 9.5.2.4.2.5Signal selection 7450
  • The signal selection module aims at selecting suitable sections of the (pre-processed) movement signals for subsequent SDB event detection. One idea underlying signal selection is that SDB event detection may be performed only on sections of the movement signals where the patient is asleep. The hypnogram output of the Sleep/Wake analysis modulecantherefore serve to gate the SDB event detection through the signal selection module. In addition, as any signal generated by gross bodily movement will overshadow the respiratory movement signal potentially associated with a SDB event, movement sections are also removed by the signal selection module, leaving only sleep-and-breathing sections for SDB event detection. Finally, given that the methods employed in the SDB event detection module are time-domain amplitude-dependent methods, it is helpful to ensure that a sufficient signal to noise ratio is present, in order to guarantee a sufficient margin to detect the drop in respiratory effort that characterisesan SDB event.
  • The signal selectionmodule works as an interface between the Sleep/Wake analysis module and the SDB event detection module. Its main function is to feed the subsequent signal processing modules only with sections of sleep and breathing and sufficient signal quality.
  • The signal selection moduleproceeds as follows.
  • The hypnogram (upsampled to the sampling rate of the movement flag series) and the movement flag series are initially combined to obtain a mask of sleep and breathing. The mask has thevalue 1 at samples where the hypnogram indicates sleep and the movement flag is false.
  • The mask of sleep and breathing is then applied to each (pre-processed) movement signal, resulting in one or more sections of variable duration.For each of these sections, a figure of merit is calculated, and a decision on whether that sectionshould be selectedis taken based on the comparison of a figure of merit with a threshold.
  • For SDB event detection, it is estimated that it should be possible to observe at least a 50% drop in a validated measure of respiratory effort. The respiratory effort measure should therefore be rarely pulled below the 50% threshold by noise. Assuming a quasi-Gaussian additive noise distribution, 97.5% of the noise samples will have peak to peak amplitude within four times the RMS noise value of a given section. For a sinusoid the ratio of peak-to-peak amplitude to RMS value is22
    Figure imgb0011
    .Therefore, to be of sufficient quality for reliable SDB event detection,a sleep-and-breathing signal section should have an RMS value that is at least given by
    Figure imgb0012
    wherermsmaxnoise is a maximum RMS value for noise.
  • The signal selection module may therefore apply a running standard deviation (RMS) filter, of duration equal to 150secondsin one implementation, to each section of sleep-and-breathing (pre-processed) movement signal. The section is deemed to be of good quality, and is therefore selected by the signal selection module, when a high percentile, set in one implementation to the 75th percentile, of the distribution of the RMS valuesfor the section exceeds a noise threshold.The noise threshold is calculated as the smaller of a maximum RMS noise value for the motion sensor 7010 (equal to 0.005 for the SleepMinder sensor unit) and the 5th percentile of the distribution of the RMS values of the pre-processed movement signal calculated for the section.
  • Under the hybridor parallel approach, each (pre-processed) movement signal is processed independently so certain sections might be selected for one channel only. The total analysis time (TAT) is calculated as the total duration of signal that has been selected for SDB event detectionin at least one channel. The TAT is used as the denominator of the AHI calculated by the feature calculation module described below.
  • The total duration of sleep-and-breathing signalsections for each channel is computed and stored. The total duration of good-quality sleep-and-breathing signal for each channel is computed and stored.The total duration of poor-quality sleep-and-breathing signal for each channel is also computed and stored.
  • To ensure that the AHI returned by the feature calculation module is reliable and representative,at least one of the following conditions may beimposed before continuing with the SDB event detection in each channel:
    • The total duration of "patient-presence" is greater than a minimum duration. In one implementation, this minimum duration is three hours, in line with standard practice in a PSG lab.
    • The total duration of good-quality sleep-and-breathing signal is greater than a minimum duration. In one implementation, this minimum duration is two hours, in line with standard practice in a PSG lab.
    • The ratio of good-quality to poor-quality sleep-and-breathing signal duration is at least 1:R. In one implementation, R was set to 2, to ensure that at least 33% of the sleep-and-breathing signal can be used for SDB event detection.
  • Otherwise, theprediction method 7300 is aborted for that channel.
  • 9.5.2.4.2.6Envelope generation 7460
  • Theenvelope generation module aims at generating a measure of the respiratory effort, in the form of an envelope that retains not only the frequency but also the amplitude content of breathing modulation.
  • In one implementation, the envelope generation module relies on a few signal processing steps. For each section of good quality sleep-and-breathing signal selected by the signal selection module any of the following may be implemented:
    • the section may be processed for outlier removal by assigningxx>prctilex95prctilex95
      Figure imgb0013
      andxx<prctilex5prctilex5
      Figure imgb0014
    • Given that the spectrum of anamplitude-modulated a respiratory movement signal (see Eq. 16) would have two small peaks at either side of the breathing rate fundamental, the section may befiltered with a bandpass filter to remove very low and high frequency components. In one version of this implementation, the bandpass filter is a second-order Butterworth filter with range [0.1 Hz, 0.8 Hz].
    • In order to maintain the amplitude information, the sectionmay befiltered with a double max&hold filter, one for positive samples and the other for negative samples, to give a positive envelope and a negative envelope.
      • ∘ The duration of the double max&hold filter can be important: too long a filter will generate a smoother envelope but will reduce the duration of dips, for averaging reasons. At the same time, too short a filter will give rise to ringing due to the nature of the respiration signal.
      • ∘ The ideal max&hold filter duration is slightly larger than a single breath duration. For this reason, the breathing ratesestimated by the breathing rate estimation module are scaled down by a factor that is slightly greater than one, to give a margin to avoid a ringing effect whilst maintaining a reasonably short (<< 2 breaths) filter duration. In one implementation, the factor is 1.25.
      • ∘ For each section, the mean value of the scaled down respirogram over the section is used as the max&hold filter duration.
    • The final envelope may be generated as the difference between the positive and negative envelopes.
  • In an alternative implementation, the envelope of each selected sectionc3of the (pre-processed) movement signal may be generated by:
    • Taking the Hilbert transformH{c3} ofc3;
    • Using the Empirical Mode Decomposition (EMD) to generate the envelopeEc3 from the Hilbert transformH{c3} as follows:
    Ec3=EMDHc3
    Figure imgb0015
  • In a variation of thealternative implementation, the envelope may be generated by lowpass filtering the modulus ofc3+jH{c3}, wherej is the square root of -1.In one version of the variation of the alternative implementation, the lowpass filter has a cutoff frequency of 0.15 Hz.
  • 9.5.2.4.2.7Modulation cycle metricscalculation 7455
  • Themodulation cycle metrics calculation module estimates the mean modulation cycle length of the patient's modulated breathing cycles to better tailor the SDB event detection module to that patient. The main challenges are the selection of correct samples to base the estimation upon and the extraction of the modulation frequency in the VLF band of the spectrum using the selected samples.
  • In one implementation, the modulation cycle metrics calculation module begins by pre-processing each selected section of the (pre-processed) movement signal in an identical manner to that of the envelope generation module described above (outlier removal and bandpass filtering).
  • Next, each pre-processed section may be normalised to zero mean and unity standard deviation, and an envelope may be generated for each normalised section using any of the methods described above in the envelope generation module.
  • For each selected section, overlapping macro-epochs may begenerated. The choice of the duration of the macro-epochs is influenced by the fact that modulated breathingcycles might last up to two minutes each for some patients and that three wavelengths are desirable for estimating the modulation cycle length. In one implementation, the macro-epochs have a duration of six minutes with an overlapping of four minutes
  • Each macro-epochmay be processed with any of the following steps:
    • The envelopemay be de-meaned.
    • The envelopemay be multiplied by a Chebichev window to avoid edge effects on the VLF section of the spectrum.
    • The fast Fourier Transform (FFT) and from it the power spectral density (PSD)may becalculated for the envelope.
    • The PSD may be interpolated to increase its resolution.
    • Peaks of the PSD may be located. Each peak corresponds to a potential modulated breathing cycle. The peak height represents the modulation power, and the peak frequency is the reciprocal of the modulation cycle length.
    • Invalid peaks may be discarded. Valid modulated breathingcycles may be defined as having:
      • ∘ A cycle length compatible with physiological range (between 30seconds and 100seconds, i.e. from 0.01 Hz to 0.033 Hz).
      • ∘ A peak power greater than a minimum power, set in one implementation to 104.
      • ∘ A clear peak, which is defined as a peak with an occupied bandwidth (OBW) at 50% of the maximum heightof less than 0.01Hz, anda height greater than 200% of the adjacent minima.
    • An extra condition may be imposed on the DC power of the PSD, namely that it does not exceed 150% of the value of the maximum peak height, in order to avoid DC related effects being marked as due to breathing modulation.
  • Based on the conditions detailed in the last point, for each macro-epoch, none, one, or more valid peaks might remain.
  • All macro-epochs for the monitoring session may then be processed with any of the following:.
    • Macro-epochs with no valid peaks are discarded.
    • Macro-epochs with only one remaining valid peak are processed first (as their estimate should be more accurate - i.e. not affected by misdetection of harmonics). The mean of the modulation cycle length (the reciprocal of the peak frequency), weighted by the logarithm of the modulation power (the peak height), is computed over all such macro-epochs.
    • For all other macro-epochs, whichcontain more than one valid peak, the closest peak to the mean modulation cycle length computed for all macro-epochs with a single peak is chosen.
    • Any valid peak with modulation cycle length falling outside the 5th or 95th percentile of the overall modulation cycle length distribution is discarded.
  • The mean of all remaining modulation cycle lengths (weighted by their modulation power) over the monitoring session maythen becomputed, together with its standard deviation and 5th, 25th, 50th, 75th and 95th percentiles.
  • One mechanism by which congestive heart failure and CSR are connected is the buildup of fluid in the pulmonary cavity, which affects the "loop gain" of the body's respiratory control system. The extent of CSR depends not only upon the raw amount of fluid in the pulmonary cavity, but also upon its distribution. This distribution changes over the monitoring session, since the person's body position has changed at the start of the session from generally vertical to generally horizontal. Therefore, the values of the extracted features may be expected to vary over of the monitoring session. The later values of those features during a monitoring session may provide a truer indication of the severity of congestive heart failure and therefore the likelihood of ADHF events that the earlier values, since by that time the fluid should have assumed a new equilibrium distribution.
  • The mean of all remaining modulation cycle lengths (weighted by their modulation power), together with its standard deviation and 5th, 25th, 50th, 75th and 95th percentiles, mayalso therefore becomputed for those periods marked as first and second halves of the main sleep period by the sleep / wake analysis module.
  • In similar fashion, values of modulation power and OBW for each macro-epoch with at least one valid peak may becalculated and stored, together with their means, standard deviations, and their 5th, 25th, 50th, 75th and 95th percentilesfor the overall monitoring session and each half of the main sleep period.
  • Under the hybrid approach, the statistics from both channels may be combined by averaging the statistics from both channels, weighted by the number of valid macro-epochs for each channel. Under the other approaches, such combination is not needed.
  • 9.5.2.4.2.8SDB event detection 7465
  • The SDB event detection module aims todetectportions of the movement signal where SDB events, including both OSA and CSR episodes, are likely to have occurred. Such portions are referred to as candidate SDB events.
  • In one implementation, the SDB event detection module uses the modulation cycle length estimated by the modulation cycle length estimation module to makea set of one or more generic SDB respiratory effort templatesspecific to thepatient 1000. The generic templates may be designed to detect a reduction in respiratory effort associated with an SDB event. By cross-correlatingthe patient-specific templates against the envelope (measure of respiratoryeffort) generated by the envelope generation module, and comparingwith a threshold, candidate SDB events may bedetected.
  • In one version of this implementation, three generic SDB respiratory effort reduction templates are defined using sine and cosine functions and a Gaussian distribution.Fig. 7icontains illustrations of three example generic SDB respiratory effort reduction templates in one versionof this implementation. Appendix A contains specifications for each of the three generic templates, parameterised by the modulation cycle lengthCL.
  • The generic templates are instantiated by filling in the modulation cycle length value estimated by the modulation cycle length estimation module as the parameterCL.
  • A correlation feature is generated by cross-correlating the envelope with each of the patient-specific templates and accepting the maximum value of the correlation values for each sample. In one implementation, this operation is performed at a small fraction, e.g. one tenth, of the sampling rate of the movement signals, to reduce the computational burden. Whenever the correlation feature exceeds a threshold, set to 0.5 in one implementation, for a time that is greater than another threshold (set in one implementation to 1/6 of the modulation cycle length or 10seconds, whichever is smaller), a candidate SDB event is detected. CandidateSDB events too close to each other, i.e. such that their mid-pointsare within half of the mean modulation cycle length, are discarded. The result is a vector of locations of candidate SDB events within the monitoring session.
  • An alternative implementation of the SDB event detection module is suitable for the combined or single-channel approach. The alternative implementation detects candidate SDBevents by comparing the drop in the respiratory effort envelope with a baselineaccording to the AASM scoring rules:
    • Hypopnea: A reduction in the airflow of ≥ 50% of baseline with 3% desaturation OR a reduction in airflow of ≥ 30% with a 4% desaturation, lasting for at least 10 seconds.
    • Apnea: A reduction in airflow of ≥ 90% of baseline lasting for at least 10 seconds.
  • In some versions of theapparatus 7000 there might be no access to the oxygen desaturation levels. Instead, three sliding windows may be utilized. The main window is the one in which the mean envelope value is computed as a proxy for the airflow. In one example, the main window is a sliding window of 10 secondswith 75% overlap. The other two windows, which surround the main window as it slides, are utilized to determine the baseline.In one example, these two baseline windows comprise the previous 35 seconds and the next 35 seconds before and after the main window. If the mean envelope value in the main window satisfies either of the above criteria (without the oxygen desaturation) with respect to the baseline defined by the mean envelope value in the two baseline windows, a candidate SDB event is detected.
  • The alternative implementation of the SDB event detection module then discards candidate SDB events of duration less than 10 seconds, in accordance with the AASM scoring rules described above.
  • A further alternative implementation of the SDB event detection module is also suitable for the combined or single-channel approach.
  • Oneversion of the further alternative implementation operates on the un-pre-processed and pre-processed movement signalsc andc3 and the envelopeEc3, and therefore does not use themodules 7410 to 7450.
  • The instantaneous power of the (un-pre-processed) movement signalc is first computed as the varianceVar ofc over a sliding window of lengthN samples:
    Figure imgb0016
  • In one version of the further alternative implementation,Var is computed on a 30-second sliding window with 75% overlap.
  • Next, the modulation depthMD of the (pre-processed) movement signalc3may beestimated. A noiseless regularly amplitude-modulated signal has the form:
    Figure imgb0017
    • whereMD is the modulation depth, varying between 0 and 1. The modulation depth of a respiratory movement signal is an indication of the severity of CSR. The modulation depthMDmay be estimated as follows:
      Figure imgb0018
      whereof andσEe3 are the standard deviations of the signal and its envelope, andSatLin is a saturation mapping to limitMD to the range [0, 1], given by
      Figure imgb0019
      wherea is set to 1, and Θ( ) is the Heaviside step function.
  • Spectral analysis provides a straightforward and robust way to extract the main harmonic of the signalc3, which is the respiratorymovement when such amovement is present. In one version of the further alternative implementation, an Auto-Regressive Yule Walker method (of order 9) may be used to estimate the Power Spectral Density (PSD) ofc3 and its envelopeEc3, thus producing two PSDs:Pc3 (ω) andPEc3 (ω).
  • The location of the highest peak of the magnitude of the PSDPc3 (ω) is used as an estimateFreq of the breathing rate:
    Figure imgb0020
  • The bandwidth of a signal may bea measure of its "irregularity". The bandwidthBW of the signalc3may be computed as
    Figure imgb0021
    whereωc3 is the location of the highest peak of the magnitude of the PSDPc3 (ω), Ω is the frequency range of interest, andc3 (ω) is the normalised PSD ofc3 computed as:
    Figure imgb0022
  • The spectral entropy takes full advantage of the previously estimated PSDs. The Normalized Spectral EntropyHxof a signalx is computed from the normalised PSD ofx as follows:
    Figure imgb0023
  • The spectral entropyHc3 of the signalc3 and the spectral entropyHEc3 of the envelopeEc3 are both computed using (Eq. 22).
  • Three categories of breathing may beidentified:
    • Regular breathing (RB), characterized by an almost constant amplitude signal in the breathing frequency band. The frequency can be time varying.
    • Irregular breathing (IB), characterized by an irregular amplitude signal in the breathing frequency band. This irregularity can be due to chest or abdomen movement irregularity, airways closures, swallowing/coughing and like behaviours.
    • Cheyne-Stokes respiration (CSR), characterized by a regularly amplitude modulated signal in the breathing frequency band.
  • The entropiesHc3 andHEc3 have characteristic behaviours depending on the breathing category. In one version of the further alternative implementation, a clustering algorithm based on Gaussian Mixture Models is applied to the entropies andHc3 andHEc3 to find an approximation of the set of three probability densities that best correspond to the three categories.In anotherversion of the further alternative implementation, a Landmark-based Spectral Clustering is applied first followed by a Gaussian fit of the probability densities of the clusters.
  • The centres (means) of the three Gaussians identified by the clustering, by either version, are expressed as 3-vectors Gc3 and GEc3.
  • The medianHhc3 of Gc3 is found and clipped above, as follows:
    Figure imgb0024
  • The entropyHc3 referred to this medianHhc3 is then inverted and saturated, such that a high value of "inverted entropy"Hi corresponds to a more regular signal:
    Figure imgb0025
    where the sigmoidal saturation functionSatNL is defined as
    Figure imgb0026
  • andλ,Tc3, andSc3 are parameters. In one version of the further alternative implementation,λ = 5,Tc3 = 1, andSc3 = 20.
  • The Cheyne-Stokes indexCS of the movement signal is then computed as follows:
    Figure imgb0027
    where
    Figure imgb0028
    andTCS,CSCS, andSCS are parameters. In one version of the further alternative implementation,TCS = 1,CSCS= 0.3,SCS = 20.
  • The following four classes of movement signals are defined:
    1. 1. Cheyne-Stokes respiration (CSR) (class CS);
    2. 2. Movement that is not CSR (class M);
    3. 3. No movement (class NM);
    4. 4. Apneas and Hypopneas (class AH).
  • Four Boolean-valued indicator or "truth" variablesCST, MT, NMT, andAHT, may becomputed as time series, indicating that the movement signal belongs to (true) or does not belong to (false) the respective classes at a given time instant. The first three truth variablesCST, MT, NMT, which are mutually exclusive in the sense that only one of the three can be true at any time, are computed by applying a set of logical rules. In one version of the further alternative implementation, the logical rules are:
    • The signal belongs to the movement class if the instantaneous power is greater than a movementthreshold, the entropy is less than an entropy threshold, and the Cheyne-Stokes index is below a Cheyne-Stokes threshold:
      Figure imgb0029
    • The signal belongs to the no-movement class if the instantaneous power is less than a no-movementthreshold and the signal and does not belong to the movement class:
      Figure imgb0030
    • The signal belongs to the CS class if the Cheyne-Stokes index is greater than the Cheyne-Stokes threshold and the the signal and does not belong to the movement class or the no-movement class:CST=CS>TCS&MT&NMT
      Figure imgb0031
  • Themovement threshold, entropy threshold, Cheyne-Stokes threshold, and the no-movement threshold valuesTM, THi, TCS, andTNM are set in one version of the further alternative implementation as follows:TM = 2,THi = 0.95,TCS = 0.1 andTNM= 0.0001TM.
  • The fourth truth variableAHT is computed using adaptive thresholding on a sliding window of lengthWAH. In oneversion of the further alternative implementation,WAN is set to 30 seconds. The value ofWAN may be increased to account for longer duration apneas or hypopneas.
  • An adaptive thresholdTAHI is computed as half the mean of the instantaneous powerVar over the window, and the truth variableAHT is true if the instantaneous power is less than the adaptive thresholdTAHI, and either the Cheyne-Stokes index is less than an apnea / hypopnea Cheyne-Stokes threshold or the entropy is greater than an apnea / hypopnea entropy threshold:AHT=Var<TAHI&CS<TCSAH|Hi>THiAH
    Figure imgb0032
  • The apnea / hypopnea Cheyne-Stokes threshold and the apnea / hypopnea entropy thresholdTCSAH andTHiAH take the following values in one version of the further alternative implementation:TCSAH = 0.1TCS andTHIAH = 0.095.
  • The candidate SDB events are the intervals in which eitherAHT orCST are true.
  • 9.5.2.4.2.9SDB event confirmation 7470
  • The event confirmation module confirms or discards each candidate SDB event based on analysis of the (pre-processed) movement signalc3corresponding with the candidate CSR event, or its envelope representing respiratory effort.
  • One implementation of the event confirmation module compares the duration and the amount of reduction in respiratory effort associated with each candidate SDB event against patient specific threshold time-domain and amplitude-domain criteria defining SDB events. This implementation of the event confirmationmodule also extracts features of the hyperpnea sectionsadjacent to the candidate SDB events to exclude misdetections due to "twitches" or other non-SDB physiological events.
  • In this implementation, the event confirmation module comprises two main stages.First, the extreme points of each candidate SDB event are located by:
    • Locating the minimum respiratory effort during the candidate SDB event.
    • Identifying all local peaks surrounding the location of minimum effort within 85% of the modulation cycle length (about a 70% margin over mean modulation cycle length value).
    • Calculating a probability pas a predefined function of the distancektbetween the location of minimum respiratory effort and each location of maximum respiratory effort on either side of it. In one implementation, the functionp[k] is defined aspk=EnvkEnv0minminkCL61,min23CLk1
      Figure imgb0033
    • whereCL is the estimated modulation cycle length.
    • Choosing the most likely maximum based on the difference in respiratory effort multiplied by the probabilityp.
    • Verifying that the minimum distance between maxima is greater than a minimum duration, set in one implementation to 10seconds.
  • Each candidate SDB event maythen beconfirmed by:
    • Calculating the minimum ratio between either maximumof respiratory effort and the minimum respiratory effort.
    • Normalizing the envelope for the candidate SDB event according to this ratio.
    • Verifying that adjacent hyperpnea sections, where the respiratory effort envelope has a magnitude greater than twice that of the minimum value, have a duration greater than a minimum'value (set to 9 seconds in one version of this implementation).
    • Verifying that the respiratory effort envelope dips below the hypopnea threshold (defined as 60% of original respiratory effort) for a time greater than one fifth of the modulation cycle length. A detected SDB event can be shorter, than 10 seconds, as the max&hold filtering applied to detect the envelope has duration larger than 2 seconds.
  • An alternative implementation of the SDB event confirmation module computes certain features from the (pre-processed) movement signalc3corresponding to each candidate SDB event, or its envelope, and applies a rule-based inference engine to the computed features to determine whether to confirm or discard each candidate SDB event.The (pre-processed) movement signalc3corresponding with each candidate SDB event is first partitioned into two periods: the apnea / hypopnea period, and the ventilatory or hyperpnea period.
  • The computed features may be some or all of the following:
    • The kurtosisKof the autocorrelationR(i) of the movement signalc3. The kurtosis is a measure of the "peakiness" of a probability distribution. A higher kurtosis indicates the candidate SDB event is less likely to be a true SDB event, whose autocorrelations tend to decay more gradually away from their peaks. The kurtosisK is computed asK=i=1PRiR4P1σR43
      Figure imgb0034
      whereP is the number of samples of the autocorrelation,R is its mean value, andσR its standard deviation.
    • The waveform lengthHwlof the hyperpneaperiodof the candidate SDB event, a feature that, as described above in relation to(Eq.10), encapsulates the amplitude, frequency, and duration of the hyperpnea sections. A higher waveform length indicates the candidate SDB event is less likely to be a true SDB event The waveform length is computed as in (Eq. 10).
    • Degree of Freedom (DOF): An indication of the complexity of the breathing pattern represented byc3. TheDOF value is computed fromc3 asDOF=n=1Nc3n2n=1Nc3n2
      Figure imgb0035
  • A movement signal with only one sharp peak would have aDOF value of nearly 1, while a sinusoidal signal would have 0 degrees of freedom. Some of the candidate SDB events might be actually related to noise-like portions in the movement signal. However, such noise-like portions are not related to normal breathing patterns, and may be discriminated by theDOF feature value, as genuine SDB events tend to exhibit lower values ofDOF.
    • Mean Envelope (ME), a feature thatindicates the respiratory effort during the candidate SDB event.If the patient is breathing normally, a sudden movement or a transient arousal could trigger a false positive SDB event detection. In order to account for such cases, the value of the 50th, 75th, and 95thpercentiles of the mean envelope value of the candidate SDB events for several patients are computed to infer what the normal values should be on average and identify the extreme values. Candidate SDB events that have higher mean envelope value than the 95thpercentile of the mean envelope values of all the candidate SDB events during a monitoring session are unlikely to be true SDB events.If the 95thpercentile of the mean envelope value is too large in comparison with other patients' mean envelope values, with a big value for the 95% percentile of the waveform length feature, the candidate SDB event is less likely to be a true SDB event.
    • Irregularity factorIR, a feature that quantifies the breath-to-breath variability in the hyperpnea section of the candidate SDB eventthat requires low computational resources. The irregularity factor is indicative of the nature of the underlying process, i.e., narrow-band or broadband. A narrow-band process is a stationary random process whose spectral density has significant values only in a band of frequencies whose width is small compared to the magnitude of the centre frequency of the band. A wide-band process has significant power terms over a wide range of frequencies.An SDB event is expected to be a narrow-band process with a low irregularity factor. In one version of the alternative implementation, theirregularity factorIR is computed for the hyperpnea sections as the ratio of the numberZCof upward zero crossings, computed as described below,to the numberNP of peaks:IR=ZCNP
      Figure imgb0036
      whereNP is computed as the square root of the ratio of the fourth moment of the hyperpnea sections to the second moment. The moments may be computed in the frequency domain, or in the time domain.
  • The rule-based inference engine applies a set of rules to the computed feature values to confirm each candidate SDB event.The candidate SDB event is confirmed or discarded depending on whether the feature values satisfy the specified rules. In one version of the alternative implementation, the inference engine applies the rulesset out in Appendix B.The alternative implementation of the SDB event confirmation module also analyses the candidate SDB events to see if they correspond to CSR events or not. As with SDB event confirmation under the alternative implementation, certain features are computed from the (pre-processed) movement signalc3corresponding with each candidate SDB event, and a rule-based inference engine is applied to the computed features to determine whether to mark each candidateSDB event as a CSR event or not.
  • The computed features are as follows:
    • Modulation cycle length (CL), defined as the time from the beginning of the apnea / hypopnea period of the SDB event to the end of the following hyperpnea period, i.e., apnea / hypopnea period length plus ventilation period length (VentILength). Atypical range forCL in CSR events is from 30 seconds to 90 seconds. The waveform length of each modulation cycle, denoted asCWL, is also computed using (Eq. 10) over the modulation cycle..
    • Number of zero crossings (ZC):This feature represents the number of times the movement signalc3crosses the x-axis. This is an indicator of how fast the movement signalc3oscillates within the modulation cycle, which in turn is an indicator of the breathing rate during the SDB event. SDB events withZC values indicating a breathing rate outside the physiological breathing range are less likely to be CSR events. For a movement signal section withN samples, the number of zero crossings feature valueZC is computed as:ZC=12n1N1sgnc3ntsgnc3n1t
      Figure imgb0037
      wheresgn() is the signum function, andt is a predetermined threshold value, set in one version to 0.
    • Phase locking value (PLV): A statistical descriptor that looks at the instantaneous phase difference between the two halves of the movement signalc3 to indicate how much the two halves resemble each other. A typical CSR event exhibits high phase similarity between the two halves due to the waxing and waning effect, and therefore a high value ofPLV, while one that is corrupted exhibits low similarity. ThePLV feature value may becomputed as follows:
      • ∘ Take the angle of the Hilbert transform of the absolute value ofc3;
      • ∘ Divide the resulting phase waveform into two halves and time-reverse the second half to obtainφ1, andφ2;
      • ∘ Apply the following equation:PLV=1Nn=0N1expjϕ1nϕ2n
        Figure imgb0038
        whereN is the number of samples in each half.
    • Signal Artefactness (SA):A binary indicator of the existence of artefacts in the movement signalc3, such as very sharp sudden peaks that do not resemble the waxing and waning shape of CSR. TheSA value is computed fromc3 as follows:wk=Θzk5σz
      Figure imgb0039
      wherez(k) is thek-th sample of absolute value ofc3andσz is the standard deviation ofz(k). SA is assigned the value of 1 ifw(k) is non-zero for any value ofh, and 0 otherwise.
    • Modulation depth (MD):This feature may becomputed as the ratio of two quantities. The first quantity (cycle percentageCP)is the duty ratio of the SDB event, i.e. the ratio of the duration of the ventilatoryperiod of the SDB event to the duration of the apnea / hypopnea period. The second quantity (the amplitude variationAV) isthe percentage change in amplitude in the ventilatory period to the amplitude in the apnea / hypopnea period, computed asAV=n=1ic3nn=iNc3n
      Figure imgb0040
      wheret is the location of transition between the ventilatory period and the apnea / hypopnea period. If the duration of the ventilatoryperiod is greater (or less) than the apnea/ hypopnea duration thenCP will be greater (or less) than 1. The same behaviour will be observed inAV ,i.e. greater than 1 if the integral of the ventilation amplitude is greater than the corresponding apnea / hypopnea amplitude, andlessthan 1 otherwise.MD is then greater than 1 if the SDB event has large amplitude variation and small cycle percentage indicating a large modulation, and less than 1 when the SDB event has a low amplitude variation and a large cycle percentage.A higher value of MD indicates a greater likelihood that an SDB event is a CSR event.
    • Rise Time (RT):Rise time may becomputed as the time required for the movement signal amplitude envelope to rise fromx% toy% of its final value, expressed as a percentage of the hyperpnea duration, wherex andy are set in one version to 0 and 95. A sudden jump to the maximum amplitude indicates that the SDB event lacks the waxing and waxing effect of a CSR event, so smaller values of rise time indicate the SDB event is less likely to be a CSR event
    • Standard Deviation of Power Spectrum AutoCorrelation (STDPSD): Each candidateSDB event is analysed with the fast Fourier transform (FFT) to obtain its corresponding power spectrum. The standard deviation of the autocorrelation of the power spectrum is then computed as another feature to distinguish CSR events from other SDB events.
    • Maximum Power Frequency (Fmax): The frequency with the maximum power value in the power spectrum of each candidateSDB event is also computed, as a CSR event tends to haveFmax values bigger than 0.15.
  • The rule-based inference engine applies a set of rules to the computed feature values to mark each candidateSDB event as CSR event, or not a CSR event. In one version of the alternative implementation, the inference engine applies the rules set out in Appendix C.
  • The alternative implementation of the SDB event confirmation module then partitions the (pre-processed) movement signal into consecutive non-overlapping segments, set in one version of the alternative implementation to 10 minutes in length. The alternative implementation of the event confirmation module then calculates how many CSR events occur in each of the segments. Each segment is marked as a CSRsegment if it contains at least 3 consecutive CSR events.
  • Finally, the alternative implementation of the SDB event confirmation module calculates the ratio of the total duration of CSR segments to the total sleep time (TST), and the ratio of the total duration of CSR segments to the length of the monitoring session (total recording time or TRT).
  • All implementations of the SDB event confirmation module conclude by storing the event duration and minimum (residual)respiratory effort for each confirmed SDB event.
  • 9.5.2.4.2.10Feature calculation 7480
  • Under the parallel or the hybrid approach, the feature calculation module first combines the confirmed SDB events in each channel by a logical OR operation. Under the combined or single-channel approach, no combination is needed.
  • In one implementation, the feature calculation module calculates the apnea / hypopnea index (AHI) as the total number of confirmed SDB events divided by the total analysis time (TAT), in hours, computed by the signal selection module.
  • From the set of confirmed SDB events,the feature calculation module also computes and stores the mean and standard deviation values for duration and residual effort of the confirmed SDB events, both for the overall monitoring session and for the first and second halves of the main sleep period.
  • A basic calculated feature setmay include some or all of the features summarised in Table 1.Table 1: Basic calculated feature set
    Feature groupDescriptionNumber of features
    Breathing RateMean, Std, 5th, 25th,50th, 75th, 95th percentiles of breathing rate estimates over all epochs7
    Sleep/WakeTotal Sleep Time, Total Time in Bed, Sleep Efficiency, un-labelled section duration4
    ActivityTotal Movement Time and percentage of intervals with non-zero activity counts2
    Mean, Std,skewness, kurtosis, and 5th, 25th,50th, 75th, 95th percentile of activity count over all intervalswith non-zero activity counts9
    Signal qualityTotal sleep-and-breathing time with good quality and poor quality2
    ConfirmedSDB eventsAHI1
    For full monitoring session:
       number of SDB events1
       mean, std, skewness, and kurtosis of SDB event duration4
       mean, std, skewness, and kurtosis of residual respiratory effort4
    For 1st and 2nd halves of main sleep period:
       number of SDB events
       meanand std of SDB event duration2
       mean and std of residual respiratory effort4 4
    Modulated breathing cycle lengthFor full night, 1st and 2nd halves of main sleep period:
       Number of modulated breathing cycles3
       Mean and std of modulation cycle length6
    For full monitoring session:
       5th, 25th,50th, 75th, 95th percentile of modulation cycle length5
    Modulated breathing cycleOBWMean, std, 5th, 25th,50th, 75th, 95th percentile of all modulated breathing cycle OBW values7
  • The feature calculation module optionally extends the basic feature set by combining the basic features in certain ways and deriving new features from the basic featuresover a single monitoring session. Table 2 summarises the single-session combined and derived features in one implementation of the feature calculation module:Table 2: Single-session combined and derived features
    Feature groupDescriptionNumber of features
    Combination of previous featuresTotal time withSDB5
    Ratio of total time with SDB to TST (mins per hour)
    Average SDB per minute of sleep
    Modulation cycle length / SDB event duration
    AHI Modulation cycle length
    Combined breathing rateDifference between the 95th percentile and the 5th, 25th, 50th, 75th percentile of all validbreathing rate estimates4
    Combined Modulation Cycle LengthDifference between the 95th percentile and the 5th, 25th, 50th, 75th percentile of all valid modulation cycle length estimates4
    Difference 2nd to 1st halfDifference between mean modulation cycle length, SDB event duration and residual effort values between the first and the second halves of themain sleep period3
    Mean over stdRatio between mean and std values for modulation cycle length, SDB event duration, and residual effort for themonitoring session3
  • The feature calculationmodule optionally further derives features from the basic featureset over multiple monitoring sessions. Table 3 summarises the multi-session derived features in one implementation of the feature calculation module. (The current monitoring session is numberedi.)Table 3: Multi-session derived features
    Feature groupDescriptionNumber offeatures
    AHI slope
    5 sessionsSlope of linear interpolation of AHI over last 5 monitoring sessionsi-4 toi1
    Breathing rate vs. baselineDifference between the 5th, 25th, 50th, 75th and 95th percentiles of all valid breathing rate estimates and. a baseline for each statistic defined as the mean of each statistic over monitoring sessionsi-7 andi-2.5
    Range featuresRange of AHI, mean breathing rate, modulation cycle length, SDB event duration, and residual effort between monitoring sessionsi-4 and i (more than two valid values are required). Modulation cycle length is normalized over mean.5
  • In an alternative implementation of feature derivation over multiple sessions, differential filtering is applied to the basic feature set. In one implementation, differential filtering comprises subtraction of each basic feature value at monitoring sessioni-N from its value at the current monitoring sessioni.
  • The calculated features may be normalised before passing to theprediction step 7330. Normalisation prevents a feature from dominating the prediction merely by virtue of having large absolute values. Conventional normalisation involves dividing the difference between each feature value and its mean value by the standard deviation of that feature value, resulting in a normalised feature with zero mean and unity standard deviation.
  • However, the calculation of mean and standard deviation of a feature value requires the whole data set to be available beforehand, which is unrealistic for real-time applications such as that of the present technology, where the sensor data is recorded and processed after each session.
  • In one form of the present technology, normalisation calculatesthe mean and standard deviation of each feature over a sliding window comprising the n most recent feature values. When the available data comprises fewer than n monitoring sessions, the mean and standard deviation are calculated over all the available data. For each feature value x, normalisation calculates:x={xmeanx1:xistdx1:xi,i<nxmeanxin:xistdxin:xi,in
    Figure imgb0041
  • In one implementation,n is set to 35.
  • In one implementation, the complete set of basic, combined, single-session-derived, and multi-session-derived features calculated by the feature calculation module are passed to theprediction step 7330.
  • In alternative implementations, only a subset of the complete set is passed to theprediction step 7330. Such implementations reduce the amount of computation required by theprediction step 7330, at the possible cost of reduced accuracy of event prediction.
  • In one implementation, the list of some or all of thefeatures passed to the predictionstep 7330is given in Table 4, which also indicates whether each feature is normalised or un-normalised:Table 4:List of features passed to thepredictionstep 7330 in one implementation.
    Feature nameFeature typeNormalised
    Total sleep timeBasicNo
    Activity 75th percentileBasic
    Modulation cycle length 50th percentileBasic
    Residual effort (2nd half- 1st half)Combined
    Apnea duration (mean / std)Single-session derived
    Modulation Cycle Length RangeMulti-session derived
    Activity 5th percentileBasicYes
    Number of SDB eventsBasic
    Breathing rate95th - 50thCombined
    Residual effort rangeMulti-session derived
  • In another implementation, the feature calculation module derives eight statistics from the four truth variablesCST, MT, NMT, andAHT: computed by the alternative implementation of the SDB event detection module:
    • CSCum andCSTot% are the total time and percentage of time the signal belonged to the Cheyne-Stokes class during the monitoring session.
    • MCum andMTot% are the total time and percentage of time the signal belonged to the movement class during the monitoring session.
    • NMCum andNMTot% are the total time and percentage of time the signal belonged to the no-movement class during the monitoring session.
    • AHCum andAHTot% are the total time and percentage of time the signal belonged to the apnea / hypopnea class during the monitoring session.
  • The percentage values are the total time values normalised by the durationD of the monitoring session.
  • The feature calculation module partitions the monitoring session intoN sub-sessionsQ(n) of equal length. The bandwidth, modulation depth and Cheyne-Stokes index valuesBW, MD andCScomputed by the alternative implementation of the SDB event detection module are summed over the CS-class periods within each sub-session, and normalised byD:BWCSQn=1DjQn,CSrj=trueBWj,
    Figure imgb0042
    MDCSQn=1DjQn,CSrj=trueMDj
    Figure imgb0043
    CSCSQn=1DjQn,CSrj=trueCSj
    Figure imgb0044
  • The inverted entropy valuesHi computed by the alternative implementation of the SDB event detection module are summed over each sub-session, and normalised byD:HiQn=1DjQnHij
    Figure imgb0045
  • In one implementation,N = 4, so the sub-sessions are quartiles.
  • In one implementation, a subset of the features calculated by the alternative implementation of the feature calculation moduleare passed to thepredictionstep 7330. One such subset comprises some or all of the six featureslisted in Table 5.Table 5: List of features passed to predictionstep 7330 in one implementation of the alternative implementation of the feature calculation module
    Feature nameFeature type
    CSCumWhole-session
    AHCumWhole-session
    MDCSQ(3)Sub-session
    MDCSQ(4)Sub-session
    CSCSQ(3)Sub-session
    CSCSQ(4)Sub-session
  • In yet another implementation, a subset of the features calculated by both implementations of the feature calculation module withN = 4 sub-sessions are normalised and passed to theprediction step 7330. One such subset is may include some or all features listed in Table 6:Table 6: List of features passed to theprediction step 7330 using both implementations of the feature calculation module
    Feature NameFeature Type
    CSTot%Whole session
    CSCSQ(2)Sub-session
    BWCSQ(1)Sub-session
    MDCSQ(3)Sub-session
    HiQ(3)Sub-session
    Breathing Rate25th percentileBasic
    Number of SDB eventsBasic
    SDB Event Duration MeanBasic
    SDB Event DurationStdBasic
    Residual Effort StdBasic
    Residual Effort Std2nd HalfBasic
    SDBEvent Duration Mean 1st halfBasic
    Modulation cyclelength
    25th percentileBasic
    Modulation cycle length 50th percentileBasic
    Modulation cycle length 75th percentileBasic
    Modulationcycle length Mean 2nd halfBasic
    Modulationcycle length Std 2nd halfBasic
    AHI Modulation cycle lengthCombined
    Breathing rate 95th - 50th percentileCombined
    Modulation Cycle Length 95th - 75th percentileCombined
    Residual effort 2nd half - 1st halfCombined
    SDB event duration 2nd half - 1st halfCombined
    Modulation Cycle Length2nd half- 1st halfCombined
    Breathing Rate50th percentile vsbaselineMulti-session derived
    Breathing Rate75th percentile vsbaselineMulti-session derived
  • In one implementation of a form of the present technology in which theprediction step 7330 is omitted, the SDBfeatures returned by thefeature extraction step 7320 are the AHI, the total sleep time (TST), the ratio of the total duration of CSR events to the total sleep time (TST), and the ratio of the total duration of CSR events to the length of the monitoring session (total recording time or TRT).
  • 9.5.2.4.2.11 Feature selection
  • Subsets of features such as thoselisted above in Table 4,Table 5, and Table 6may be obtained by feature selection. Feature selection aims to identify a subset of the completefeatureset thatallows thepredictionstep 7330 to efficiently predict clinical eventsfrom unseen data with reasonable accuracy.
  • Onescheme for feature selection is termed differential evaluation feature selection (DEFS).DEFS uses a pre-specifiednumber of features to be selected, population size, and number of iterations. DEFS first generates from the completefeature set a population of subsets equal to the pre-specified population size. Each subset comprisesa number of randomly selected features equal to the pre-specified number of features. DEFS then applies a perturbation to each of the generated subsets and determines whether each perturbed subset should replace the corresponding generated subset in the population. The perturbation and replacement steps are repeated for the pre-specified number of iterations. For all iterations, the determination of replacement is made using a predetermined figure of merit, by determining whether the perturbed subset yields a better figure of merit than its counterpart. After all iterations are complete, the subset in the population with the best figure of merit is returned as the selected subset.
  • The predetermined figure of merit is based on the performance of theprediction step 7330 on training data. The training data set comprises multiple monitoring sessions of data obtained from multiple patients. At least some of the sessions in the training data set are associated with a clinical event that has been identified by a clinical expert in the corresponding patient in the period immediately following the associated session. Features are shifted by one monitoring session to ensure themonitoring apparatus 7000 is genuinely predictive (i.e. features at sessionn cannot be used to predict a clinical event at session n).
  • To compute the figure of merit for a given subset, for each patient in the training set, the prediction step 7330 (if training is needed) is trained using the, sessions from all but that patient, and the trained prediction is carried out on the sessions from that patient to obtain the true positive (TP), false positive (FP), false negative (FN) and true negative (TN) performance ratios for the subset.
  • In one implementation of DEFS, the figure of merit is the maximum specificityallowing at least 75% of sensitivity, to ensure a steep rise in the receiver operating curve (ROC). A higher figure of merit indicates better performance.
  • In an alternative implementation of DEFS, the figure of merit is the ratio of the false positive coverage (FPCoverage), which is the area covered by false positives and is inversely related to specificity, to the sensitivity (TP/(TP+FN)). The FPCoverage and sensitivity are set to have upper and lower bounds of 40% and 75% respectively. A lower figure of merit indicates better performance.
  • In an optional extension of the above DEFS implementation, the numberof features selected is reduced from the pre-specified number by identifying all sub-subsets of the subset selected by DEFS, evaluating the performance of each sub-subset against that of the full subset, and choosing asub-subset whose performance does not decrease significantly against that of the full subset, as judged by the figure of merit. This extensiontypically reduces the number of selected features by two.
  • Another optional extension is a voting system, in which multiple rounds of DEFS are performed, each one specifying a larger number of features than the originally pre-specified number. The number of features is then reduced using a voting scheme on all the selected subsets, whereby a feature is discardedunless least a certain percentage (e.g. 80%) of the selectedsubsets included the feature.
  • 9.5.2.4.3Prediction 7330
  • Theprediction step 7330 generates a Boolean indication of whether a clinical event is likely to occur within the predetermined prediction horizon, from the vector xof SDBfeatures passed by thefeature extraction step 7320.
  • Fig. 7j is a flow chart illustrating amethod 7900 that may be used to implement theprediction step 7330 in one form of the present technology. Themethod 7900 starts atstep 7910, which applies State-Space Principal Component Analysis (SSPCA) to generate the principal componentsS1,S2, ... of the feature vectorx. SSPCA is equivalent to a self-tuning linear filter bank with orthogonalising properties that is applied to reduce the dimensionality of the feature space.
  • In one implementation ofstep 7910, SSPCA starts by embedding the SDB feature vector x, and its predecessors from the preceding monitoring sessions, in a higher-dimensional space to generate a trajectory matrix Z. The embedding requires two parameters: the embedding lagL, and the embedding dimensionN:Z=x10x1L1x1NLx1N+1L1x20x2L1x2NLx2N+1L1
    Figure imgb0046

    wherexi(j) is the value of thei-th component of the feature vector x at the monitoring session indexed byj. The dimensions of Z areM(N+1) rows byL columns, where M is the number of selected features. In one implementation,L = 1 andN = 30.
  • SSPCA then performs a singular value decomposition of the trajectory matrix Z:Z=PSDPET
    Figure imgb0047

    where D has theL singular valuesdiof Z in descending order on its diagonal with zeros elsewhere, and PS and PE are square unitary matrices whose columns are the left and right singular vectors si and ei respectively of Z, satisfyingZei=disi
    Figure imgb0048
  • The state space principal component matrixSSPC is then computed from the largestn0 singular valuesdi by projecting the trajectory matrix Z onto the correspondingn0 left singular vectors si:SSPC=PSTZ
    Figure imgb0049
  • The matrixSSPC hasn0 rows andL columns. The rows of the matrix SSPCarethen0 principal componentsS1.,S2, ...,Sn0 of the feature vector x.In one implementation,no is set to 4.
  • In an optional final step of SSPCA, then0 principal componentsS1.,S2, ...,Sn0 (the rows of the matrixSSPC) areeach bandpass filtered to the frequency band [0.001 Hz, 0.05 Hz] using a second order Butterworth filter.
  • Returning to themethod 7900, an optional step 7920 (shown dashed inFig. 7j) estimates the coefficientsH of an adaptive predictive linear (APL) model for the principal componentSlover the predetermined prediction horizon.In one implementation, the APL model is an Auto-Regressive Moving-Average model with exogenous input (ARMAX) model oforder 12, and the prediction horizon is seven sessions. A least mean square (LMS) algorithm may be used to estimate the coefficientsH of the APL model for the principal componentS1.
  • A further optional step 7930 (also shown dashed inFig. 7j) then computes a differential measureW of the APL model coefficientsH computed by thestep 7920. The reason for using the differential operator to obtain the differential measureW is that the rate of change of the APL model coefficientsH, rather than their absolute value, is of interest for prediction purposes. In one implementation, the differential measureWis computed as follows:Wn=niHi2n
    Figure imgb0050
  • Finally,step 7940 takes one or more of the principal componentsS1,S2, ...,,and the differential measureWif theoptional steps 7920 and 7930 if were performed, and generates a Boolean indication of whether a clinical event is likely to occur within the prediction horizon, as described in more detail below. Themethod 7900 then concludes.
  • In one implementation of theprediction step 7940, suitable for the case wheresteps 7920 and 7930 were used to compute the differential measureW, a heuristic rule is used to generate the Boolean indication. In this implementation, the Boolean indication Pis a binary-valued (1 = True, 0 = False) function of the principal componentS1, the differential measureW, and three thresholdsTa, Tw, andTn:P=ΘS1Ta1ΘWTw+1ΘS1Tn
    Figure imgb0051

    whereΘ is the Heaviside step function. The thresholdsTa, Tw, andTn are chosen in the following ranges dependent on the extreme values ofS1 andW:Ta00.1maxS1Tw00.1maxWTn00.3minS1
    Figure imgb0052
  • In another implementation of theprediction step 7940, suitable for the case wheresteps 7920 and 7930 have been omitted, a differentheuristic rule is applied to generate the Boolean indicationP from the first two principal componentsS1 andS2. Under this heuristic rule, P is true if bothS1 andS2 lie within predetermined ranges (T1I, T1S) and (T2I, T2S) respectively:P=S1>S1I&S1<T1S&S2>T2I&S2<T2S
    Figure imgb0053

    whereT1I,T1S,T2I andT2S are predetermined endpoints. In one implementation, the following endpoints are used:T1I =T2I=0.35;T1S =T2S=20.
  • In other implementations of theprediction step 7940,a classifieris applied to estimate the posterior probability of its input vector y belonging to each of c output classes, one of which is a "no-event-occurring" class and the remainder being associated with various types of clinical event occurring during the predetermined prediction horizon.Each estimated posterior probability is compared with a posterior probability threshold. If the posterior probability of anyclass associated with a clinical event occurring is greater than the posterior probability threshold, the Boolean indication is set to True; otherwise, the Boolean indication is set to False.
  • In some classifier-based implementations of theprediction step 7940, the input vector y to the classifier is one or more of the principal componentsS1., S2, ...,Sn0 and the differential measureW (if computed).
  • In one such implementation of theprediction step 7940, the classifier is a Quantum Neural Network (QNN) applied to the principal componentS1 and the differential measureW. The QNN is first trained on training data comprising multiple input vectors with respective associated class labels. A QNN works as a fuzzy nonlinear inference system and can approximate complex functions with very few hidden neurons.
  • In further such implementation of theprediction step 7940, the classifier is a naive Bayesian classifier applied to the principal componentS1 and the differential measureW. The Bayesian classifier is naive in that it assumes the independence of the classes.
  • In other such implementations of theprediction step 7940, a QNN or a Bayesian classifier as described above is applied to the first k principal componentsS1, ...,Sk, omitting the differential measureW.
  • In an altemativeimplementation of theprediction step 7330, thesteps 7910, 7920, and 7930 are omitted, and the input vector y to the classifier used atstep 7940 is simply theSDB feature vector x. Such "direct" implementations ofstep 7330 are less computationally intensive than those using thecomplete method 7900, provided the feature vector x is not too long.
  • In one such implementation, the classifier used atstep 7940 is a linear discriminant analysis (LDA) classifier. The basic idea of LDA classification is to find a linear combination of features which characterize or separate different classes. LDA does not require multiple passes over the data for parameter optimization and naturally handles problems with more than two classes.
  • An LDA classifier estimates the posterior probabilityPkof a given input vector y belonging to eachof c classes indexed byk = 1, ...,casPk=expzkI=1cexpzl
    Figure imgb0054

    wherez=W0+W1y
    Figure imgb0055

    is a linear transformation of the vector y to ac-vectorz.
  • The parametersW0(ac-vector) andW1(ac-byNf matrix, whereNf is the length of the input vector y) of the linear transformation are obtained by training the LDA classifier on training data comprising multiple vectors with respective associated class labels. The class means µk and covariancesΣk of the training vectors in each class k are first obtained. The common covariance Σ is then computed as the weighted sum of the class covariancesΣk. The weights of all classes are set to 1/c in one implementation. In an alternative implementation, the weight of each class is the fraction of training vectors labelled with that class.
  • Thek-th row of the linear transformation parametersW0 andW1are then computed for each classkasW0,k=12μkTΣ1μk+logπk
    Figure imgb0056
    W1,k˙=μkTΣ1
    Figure imgb0057

    where theπk are the prior class probabilities, set to 1/k in one implementation.
  • If the input vector y contains one or more missing features (i.e. components set to NaN), as is not uncommon for movement data obtained from contactless motion sensors, the linear transformation parametersdefined by (Eq. 55) and (Eq. 56) cannot be applied to the incomplete feature vector y as in (Eq. 54). For such incomplete feature vectorsy, "reduced" class means µk' and covariancesΣk' are computed for each classkbased only on the available features in the incomplete input feature vector y. A reduced common covariance matrixΣ' is then computed as the weighted sum of the reduced class covariancesΣk' as above. "Reduced" linear transformation parametersW0'andW1' are then computed from the reduced class means and the reduced common covariance matrix Σ' using (Eq. 55) and (Eq. 56). Finally, the linear transformation (Eq. 54) using the "Reduced" linear transformation parametersW0'andW1' is applied to the incomplete feature vector y to obtain the posterior probabilitiesPk.
  • In classifier-based implementations of theprediction step 7940, the number c of classes is usually two, since the training data vectors have only two labels: event predicted, or event not predicted. However, in some implementations, the eventpredicted class may be subdivided into sub-classes associated with different predicted events by first clustering the associated vectors into sub-classes, e.g. by k-means clustering.
  • In classifier-based implementations of theprediction step 7940, the value of the posterior probability threshold needs to be set. In some versions of these implementations, the training data set is used to set the posterior probability threshold to the value that minimises the false positive coverage in the ROC for a sensitivity value greater or equal than a threshold, set in one implementation to 75%.
  • In other versions of these implementations, the setting of the posterior probability threshold is combined with feature selection, by making the posterior probability threshold an extra parameter to be optimised by the DEFS method described above, constrained to lie within the range [0, 1].
  • In accordance with one application of themonitoring apparatus 7000, where an alertis to be provided between sessionn-7 and sessionn-1 for a clinical event predicted at session n, i.e. a seven-session prediction horizon, each positive prediction is expanded by seven sessions into the future. This modification was included in the calculation of sensitivity and false positive coverage used in classifier training and feature selection.
  • Also, for training purposes, the reverse of this operation was performed on the clinical expert evaluations, with smearing between sessionn-7 and sessionn-1 for a clinical event deemed to occur at sessionn. This was only applied on training data as it was found to be the most effective range for enhancing classifier performance.
  • 9.6 GLOSSARY
  • For the purposes of the present technology disclosure, in certain forms of the present technology, one or more of the following definitions may apply. In other forms of the present technology, alternative definitions may apply.
  • 9.6.1 General
  • Air: In certain forms of the present technology, air supplied to a patient may be atmospheric air, and in other forms of the present technology atmospheric air may be supplemented with oxygen.
  • Continuous Positive Airway Pressure (CPAP): The application of a supply of air or breathable gas to the entrance to the airways at a pressure that is continuously positive with respect to atmosphere, and preferably approximately constant through a respiratory cycle of a patient In some forms, the pressure at the entrance to the airways will vary by a few centimeters of water within a single respiratory cycle, for example being higher during inhalation and lower during exhalation. In some forms, the pressure at the entrance to the airways will be slightly higher during exhalation, and slightly lower during inhalation. In some forms, the pressure will vary between different respiratory cycles of the patient, for example being increased in response to detection of indications of partial upper airway obstruction, and decreased in the absence of indications of partial upper airway obstruction.
  • 9.6.2 Aspects of PAP devices
  • Air circuit: A conduit or tube constructed and arranged in use to deliver a supply of air or breathable gas between a PAP device and a patient interface. In particular, the air circuit may be in fluid connection with the outlet of the pneumatic block and the patient interface. The air circuit may be referred to as air delivery tube. In some cases there may be separate limbs of the circuit for inhalation and exhalation. In other cases a single limb is used.
  • Blower or flow generator: A device that delivers a flow of air at a pressure above ambient pressure.
  • Controller: A device, or portion of a device that adjusts an output based on an input. For example one form of controller has a variable that is under controlthe control variable- that constitutes the input to the device. The output of the device is a function of the current value of the control variable, and a set point for the variable. A servo-ventilator may include a controller that has ventilation as an input, a target ventilation as the set point, and level of pressure support as an output. Other forms of input may be one or more of oxygen saturation (SaO2), partial pressure of carbon dioxide (PCO2), movement, a signal from a photoplethysmogram, and peak flow. The set point of the controller may be one or more of fixed, variable or learned. For example, the set point in a ventilator may be a long term average of the measured ventilation of a patient. Another ventilator may have a ventilation set point that changes with time. A pressure controller may be configured to control a blower or pump to deliver air at a particular pressure.
  • Therapy: Therapy in the present context may be one or more of positive pressure therapy, oxygen therapy, carbon dioxide therapy, control of dead space, and the administration of a drug.
  • Positive Airway Pressure (PAP) device: A device for providing a supply of air at positive pressure to the airways.
  • Transducers: A device for converting one form of energy or signal into another. A transducer may be a sensor or detector for converting mechanical energy (such as movement) into an electrical signal. Examples of transducers include pressure sensors, flow sensors, carbon dioxide (CO2) sensors, oxygen (O2) sensors, effort sensors, movement sensors, noise sensors, a plethysmograph, and cameras.
  • 9.6.3 Aspects of the respiratory cycle
  • Apnea: Apnea is said to have occurred when flow falls below a predetermined threshold for a duration, e.g. 10 seconds. An obstructive apnea will be said to have occurred when, despite patient effort some obstruction of the airway does not allow air to flow. A central apnea will be said to have occurred when an apnea is detected that is due to a reduction in respiratoryeffort, or the absence of respiratoryeffort.
  • Breathing rate: The rate of spontaneous respiration of a patient, usually measured in breaths per minute.
  • Duty cycle: The ratio of inhalation time,Ti to total breath time,Ttot.
  • Effort (respiratory): The work done by a spontaneously breathing person attempting to breathe.
  • Expiratory portion of a breathing cycle: The period from the start of expiratory flow to the start of inspiratory flow.
  • Flow limitation: Preferably, flow limitation will be taken to be the state of affairs in a patient's respiration where an increase in effort by the patient does not give rise to a corresponding increase in flow. Where flow limitation occurs during an inspiratory portion of the breathing cycle it may be described as inspiratory flow limitation. Where flow limitation occurs during an expiratory portion of the breathing cycle it may be described as expiratory flow limitation.
  • Hypopnea: Preferably, a hypopnea will be taken to be a reduction in flow, but not a cessation of flow. In one form, a hypopnea may be said to have occurred when there is a reduction in flow below a threshold for a duration. In one form in adults, the following either of the following may be regarded as being hypopneas:
    1. (i) a 30% reduction in patient breathing for at least 10 seconds plus an associated 4% desaturation; or
    2. (ii) a reduction in patient breathing (but less than 50%) for at least 10 seconds, with an associated desaturation of at least 3% or an arousal.
  • Hyperpnea: An increase in flow to a level higher than normal flow.
  • Inspiratory portion of a breathing cycle: Preferably the period from the start of inspiratory flow to the start of expiratory flow will be taken to be the inspiratory portion of a breathing cycle.
  • Patency (airway): The degree of the airway being open, or the extent to which the airway is open. Apatent airway is open. Airway patency may be quantified, for example with a value of one (1) being patent, and a value of zero (0), being closed.
  • Respiratory flow, airflow, patient airflow, respiratory airflow (Qr): These synonymous terms may be understood to refer to the PAP device's estimate of respiratory airflow, as opposed to "true respiratory flow" or "true respiratory airflow", which is the actual respiratory flow experienced by the patient, usually expressed in litres per minute.
  • Upper airway obstruction (UAO): includes both partial and total upper airway obstruction. This may be associated with a state of flow limitation, in which the level of flow increases only slightly or may even decrease as the pressure difference across the upper airway increases (Starling resistor behaviour).
  • 9.6.4 PAP device parameters
  • Flow rate: The instantaneous volume (or mass) of air delivered per unit time. While flow rate and ventilation have the same dimensions of volume or mass per unit time, flow rate is measured over a much shorter period of time. Flow may be nominally positive for the inspiratory portion of a breathing cycle of a patient, and hence negative for the expiratory portion of the breathing cycle of a patient. In some cases, a reference to flow rate will be a reference to a scalar quantity, namely a quantity having magnitude only. In other cases, a reference to flow rate will be a reference to a vector quantity, namely a quantity having both magnitude and direction. Flow will be given the symbolQ. Total flow,Qt, is the flow of air leaving the PAP device. Vent flow,Qv, is the flow of air leaving a vent to allow washout of exhaled gases. Leak flow,Ql, is the flow rate of unintentional leak from a patient interface system. Respiratory flow,Qr, is the flow of air that is received into the patient's respiratory system.
  • Leak: Preferably, the word leak will be taken to be a flow of air to the ambient. Leak may be intentional, for example to allow for the washout of exhaled CO2. Leak may be unintentional, for example, as the result of an incomplete seal between a mask and a patient's face.
  • Pressure: Force per unit area. Pressure may be measured in a range of units, including cmH2O, g-f/cm2, hectopascal. 1cmH2O is equal to 1 g-f/cm2 and is approximately 0.98 hectopascal. In this specification, unless otherwise stated, pressure is given in units of cmH2O. For nasal CPAP treatment of OSA, a reference to treatment pressure is a reference to a pressure in the range of about 4-20 cmH2O, or about 4-30 cmH2O. The pressure in the patient interface is given the symbolPm.
  • 9.6.5 Anatomy of the respiratory system
  • Diaphragm: A sheet of muscle that extends across the bottom of the rib cage. The diaphragm separates the thoracic cavity, containing the heart, lungs and ribs, from the abdominal cavity. As the diaphragm contracts the volume of the thoracic cavity increases and air is drawn into the lungs.
  • Larynx: The larynx, or voice box houses the vocal folds and connects the inferior part of the pharynx (hypopharynx) with the trachea.
  • Lungs: The organs of respiration in humans. The conducting zone of the lungs contains the trachea, the bronchi, the bronchioles, and the terminal bronchioles. The respiratory zone contains the respiratory bronchioles, the alveolar ducts, and the alveoli.
  • Nasalcavity: The nasal cavity (or nasal fossa) is a large air filled space above and behind the nose in the middle of the face. The nasal cavity is divided in two by a vertical fin called the nasal septum. On the sides of the nasal cavity are three horizontal outgrowths called nasal conchae (singular "concha") or turbinates. To the front of the nasal cavity is the nose, while the back blends, via the choanae, into the nasopharynx.
  • Pharynx: The part of the throat situated immediately inferior to (below) the nasal cavity, and superior to the oesophagus and larynx. The pharynx is conventionally divided into three sections: the nasopharynx (epipharynx) (the nasal part of the pharynx), the oropharynx (mesopharynx) (the oral part of the pharynx), and the laryngopharynx (hypopharynx).
  • 9.7 OTHER REMARKS
  • A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.
  • Unless the context clearly dictates otherwise and where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit, between the upper and lower limit of that range, and any other stated or intervening value in that stated range is encompassed within the technology. The upper and lower limits of these intervening ranges, which may be independently included in the intervening ranges, are also encompassed within the technology, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the technology.
  • Furthermore, where a value or values are stated herein as being implemented as part of the technology, it is understood that such values may be approximated, unless otherwise stated, and such values may be utilized to any suitable significant digit to the extent that a practical technical implementation may permit or require it.
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this technology belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present technology, a limited number of the exemplary methods and materials are described herein.
  • When a particular material is identified as being preferably used to construct a component, obvious alternative materials with similar properties may be used as a substitute. Furthermore, unless specified to the contrary, any and all components herein described are understood to be capable of being manufactured and, as such, may be manufactured together or separately.
  • It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include their plural equivalents, unless the context clearly dictates otherwise.
  • All publications mentioned herein disclose and describe the methods and/or materials which are the subject of those publications. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present technology is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates, which may need to be independently confirmed.
  • Moreover, in interpreting the disclosure, all terms should be interpreted in the broadest reasonable manner consistent with the context. In particular, the terms "comprises" and "comprising" should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly referenced.
  • The subject headings used in the detailed description are included only for the ease of reference of the reader and should not be used to limit the subject matter found throughout the disclosure or the claims. The subject headings should not be used in construing the scope of the claims or the claim limitations.
  • Although the technology herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the technology. In some instances, the terminology and symbols may imply specific details that are not required to practice the technology. For example, although the terms "first" and "second" may be used, unless otherwise specified, they are not intended to indicate any order but may be utilised to distinguish between distinct elements. Furthermore, although processsteps in the methodologies may be described or illustrated in an order, such an ordering is not required. Those skilled in the art will recognize that such ordering may be modified and/or aspects thereof may be conducted concurrently or even synchronously.9.8 REFERENCE LABELS LIST
    patient1000
    sensor unit1200
    patient interface3000
    pap device4000
    external housing4010
    upper portion4012
    portion4014
    panel4015
    chassis4016
    handle4018
    pneumatic block4020
    pneumatic component4100
    air circuit4170
    electrical component4200
    processes4300
    humidifier5000
    water reservoir5110
    heating plate5120
    apparatus7000
    microcontroller unit MCU7001
    memory7002
    movement signal7003
    I signal7003a
    Q signal7003b
    communications communications circuitry7004
    external computing device7005
    processor7006
    connection7008
    contactless motion sensor7010
    display device7015
    audio output7017
    transmitter7020
    receiver7030
    local oscillator7040
    antenna7050
    signal7060
    signal7070
    mixer7080
    method7100
    first step7110
    step7120
    step7130
    step7140
    arrow7145
    step7150
    step7160
    step7170
    arrow7175
    arrow7178
    step7180
    method7200
    step7210
    step7220
    step7230
    prediction method7300
    step7310
    step7320
    step7330
    block diagram7400
    module7410
    presence / Absence detection module7420
    sleep / wake analysis module7430
    breathing rate estimation module7440
    signal selection module7450
    modulation cycle metrics calculation module7455
    envelope generation module7460
    sdb event detection module7465
    sdb event confirmation module7470
    feature calculation module7480
    block diagram7500
    movement detection module7510
    presence / absence detection module7520
    sleep / wake analysis module7530
    breathing rate estimation module7540
    signal selection module7550a
    signal selection module7550b
    modulation cycle metrics calculation module7555
    envelope generation module7560a
    envelope generation module7560b
    sdb event detection module7565a
    sdb event detection module7565b
    sdb event confirmation module7570a
    sdb event confirmation module7570b
    feature calculation module7580
    method7900
    step7910
    step7920
    step7930
    step7940
  • APPENDIX A
  • k ranges from-CL/2 toCL/2.
    • Template 1:t1k=12πβexpk22β
      Figure imgb0058
      whereβ= 6000.
    • Template 2:t2k={cosCL4+1,CL2k<CL40,CL4k<0sinkCL4πCL4+1,0k<CL2
      Figure imgb0059
    • Template 3:t3k=t2k
      Figure imgb0060
    APPENDIX B
  • Figure imgb0061
    Figure imgb0062
    Figure imgb0063
    Figure imgb0064
  • APPENDIX C
  • Figure imgb0065

Claims (12)

  1. A cardio-pulmonary health monitoring system (7000) comprising:
    at least one sensor (1200) adapted to generate data related to the cardio-pulmonary health of a patient (1000);
    a display (7015); and
    a controller (7001, 7006) coupled to the at least one sensor (1200), wherein the controller (7001, 7006) is configured to:
    extract at least one respiratory parameter from the data generated by the at least one sensor (1200) during one or more monitoring sessions;
    analyse the at least one respiratory parameter extracted during the one or more monitoring sessions;
    trigger generation on the display (7015) of at least one query based on the analysis of the at least one respiratory parameter, the at least one query being configured to prompt the patient (1000) for an input to the controller (7001, 7006);
    characterized in that the controller is further configured to:
    adjust a treatment control parameter of a Positive Airway Pressure (PAP) device (4000) based on the patient input to the controller (7001, 7006) that is prompted by the at least one query, the PAP device (4000) being configured to generate a flow of breathable gas to a patient interface (3000); and
    trigger generation of a clinical alert based on the patient input to the controller (7001, 7006) that is prompted by the at least one query.
  2. A cardio-pulmonary health monitoring system (7000) according to claim 1, further comprising a memory (7002) including a data structure of questions, each question being associated with a detectable condition of the at least one respiratory parameter.
  3. A cardio-pulmonary health monitoring system (7000) according to claim 2, wherein a question addresses medication compliance and/or dietary compliance.
  4. A cardio-pulmonary health monitoring system (7000) according to any of claims 2 to 3, wherein the controller (7001, 7006) is further configured to select a first question in response to a detected condition of the respiratory parameter, and based on a response to the first question, continue to analyse the at least one respiratory parameter in a subsequent monitoring session before generating a clinical alert.
  5. A cardio-pulmonary health monitoring system (7000) according to claim 4, wherein the controller (7001, 7006) is further configured to trigger generation of the clinical alert following the subsequent monitoring session, and the generation of the clinical alert is based on a patient response to a second question generated by the controller (7001, 7006).
  6. A cardio-pulmonary health monitoring system (7000) according to any of claims 1 to 5, further comprising the PAP device (4000).
  7. A cardio-pulmonary health monitoring system (7000) according to any of claims 1 to 6, wherein the treatment control parameter comprises a target ventilation.
  8. A cardio-pulmonary health monitoring system (7000) according to any of claims 1 to 7, wherein triggering generation of the clinical alert comprises displaying a warning on a display (7015) and/or transmitting an electronic message from a communications device (7004).
  9. A cardio-pulmonary health monitoring system (7000) according to any of claims 1 to 8, wherein the analysis of the at least one respiratory parameter comprises a detection of dyspnoea.
  10. A cardio-pulmonary health monitoring system (7000) according to any of claims 1 to 9, wherein the analysis of the at least one respiratory parameter comprises extracting sleep disordered breathing features.
  11. A cardio-pulmonary health monitoring system (7000) according to claim 10, wherein the data generated by the sensor (1200) comprises movement signals representing movement of the patient (1000).
  12. A cardio-pulmonary health monitoring system (7000) according to claim 11, wherein the analysis of the at least one respiratory parameter further comprises predicting whether a clinical event is likely to occur within a predetermined prediction horizon based on the extracted sleep disordered breathing features.
EP19191677.4A2012-05-302013-05-30Apparatus for monitoring cardio-pulmonary healthActiveEP3639733B1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
EP22202980.3AEP4154804A1 (en)2012-05-302013-05-30Apparatus for monitoring cardio-pulmonary health

Applications Claiming Priority (6)

Application NumberPriority DateFiling DateTitle
IE201202542012-05-30
AU2012902693AAU2012902693A0 (en)2012-06-26Methods and Apparatus for Monitoring and Treating Respiratory Insufficiency
AU2012905221AAU2012905221A0 (en)2012-11-30Method and Apparatus for the Detection and Treatment of Respiratory Disorders
AU2013901482AAU2013901482A0 (en)2013-04-29Method and apparatus for predicting cardio-pulmonary events
PCT/AU2013/000564WO2013177621A1 (en)2012-05-302013-05-30Method and apparatus for monitoring cardio-pulmonary health
EP13796432.6AEP2854636B1 (en)2012-05-302013-05-30Method and apparatus for monitoring cardio-pulmonary health

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
EP13796432.6ADivisionEP2854636B1 (en)2012-05-302013-05-30Method and apparatus for monitoring cardio-pulmonary health

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
EP22202980.3ADivisionEP4154804A1 (en)2012-05-302013-05-30Apparatus for monitoring cardio-pulmonary health

Publications (3)

Publication NumberPublication Date
EP3639733A2 EP3639733A2 (en)2020-04-22
EP3639733A3 EP3639733A3 (en)2020-07-29
EP3639733B1true EP3639733B1 (en)2022-10-26

Family

ID=49672180

Family Applications (3)

Application NumberTitlePriority DateFiling Date
EP22202980.3AWithdrawnEP4154804A1 (en)2012-05-302013-05-30Apparatus for monitoring cardio-pulmonary health
EP19191677.4AActiveEP3639733B1 (en)2012-05-302013-05-30Apparatus for monitoring cardio-pulmonary health
EP13796432.6AActiveEP2854636B1 (en)2012-05-302013-05-30Method and apparatus for monitoring cardio-pulmonary health

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
EP22202980.3AWithdrawnEP4154804A1 (en)2012-05-302013-05-30Apparatus for monitoring cardio-pulmonary health

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
EP13796432.6AActiveEP2854636B1 (en)2012-05-302013-05-30Method and apparatus for monitoring cardio-pulmonary health

Country Status (6)

CountryLink
US (3)US10426380B2 (en)
EP (3)EP4154804A1 (en)
JP (4)JP6655991B2 (en)
CN (3)CN104736055A (en)
AU (2)AU2013270443B2 (en)
WO (1)WO2013177621A1 (en)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US8437843B1 (en)2006-06-162013-05-07Cleveland Medical Devices Inc.EEG data acquisition system with novel features
US9202008B1 (en)*2007-06-082015-12-01Cleveland Medical Devices Inc.Method and device for sleep analysis
US10426399B1 (en)*2007-06-082019-10-01Cleveland Medial Devices Inc.Method and device for in-home sleep and signal analysis
US8826473B2 (en)2011-07-192014-09-09Hill-Rom Services, Inc.Moisture detection system
US8870764B2 (en)2011-09-062014-10-28Resmed Sensor Technologies LimitedMulti-modal sleep system
JP6655991B2 (en)*2012-05-302020-03-04レスメッド センサー テクノロジーズ リミテッド Method and apparatus for monitoring cardiopulmonary health
US10525219B2 (en)2012-06-262020-01-07Resmed Sensor Technologies LimitedMethods and apparatus for monitoring and treating respiratory insufficiency
US9757560B2 (en)2013-11-192017-09-12The Cleveland Clinic FoundationSystem and method for treating obstructive sleep apnea
EP3111351B1 (en)*2014-02-272023-12-20Technion Research & Development Foundation Ltd.Device and method for monitoring respiratory effort using energy index
DE102014003542B4 (en)*2014-03-122021-09-30Drägerwerk AG & Co. KGaA Method and device for generating an alarm during mechanical patient ventilation
CN116570245A (en)2014-05-262023-08-11瑞思迈传感器技术有限公司 Methods and devices for monitoring chronic diseases
US9931483B2 (en)*2014-05-282018-04-03Devilbiss Healtcare LlcDetection of periodic breathing during CPAP therapy
US11386998B2 (en)2014-08-072022-07-12Board Of Regents Of The University Of NebraskaSystems and techniques for estimating the severity of chronic obstructive pulmonary disease in a patient
TWI549090B (en)*2014-08-292016-09-11 Portable sensing operation device
JP6676877B2 (en)*2015-03-092020-04-08富士通株式会社 Meal time estimation method, meal time estimation device, and meal time estimation program
JP7258461B2 (en)*2015-03-132023-04-17レスメド・プロプライエタリー・リミテッド Respiratory therapy device and method
CN104757967A (en)*2015-04-272015-07-08张政波Cardiopulmonary coupling feedback method and device
US11771365B2 (en)2015-05-132023-10-03ResMed Pty LtdSystems and methods for screening, diagnosis and monitoring sleep-disordered breathing
US10542961B2 (en)2015-06-152020-01-28The Research Foundation For The State University Of New YorkSystem and method for infrasonic cardiac monitoring
WO2017026282A1 (en)*2015-08-102017-02-16コニカミノルタ株式会社System for monitoring person to be monitored, monitoring information screen display device, and monitoring information screen display method
CN108135534B (en)2015-08-262022-04-05瑞思迈传感器技术有限公司System and method for monitoring and managing chronic diseases
PT3359037T (en)*2015-10-072025-01-31Precordior OyMethod and apparatus for producing information indicative of cardiac condition
WO2017097907A1 (en)*2015-12-082017-06-15Resmed LimitedNon-contact diagnosis and monitoring of sleep disorders
WO2017119638A1 (en)*2016-01-082017-07-13전남대학교산학협력단Real-time sleep disorder monitoring apparatus
US10537253B2 (en)*2016-02-252020-01-21Samsung Electronics Company, Ltd.Detecting live tissues using signal analysis
US12303253B2 (en)2016-03-312025-05-20Zoll Medical CorporationSystems and methods of tracking patient movement
EP4503052A3 (en)2016-04-012025-08-27Cardiac Pacemakers, Inc.Systems and methods for detecting worsening heart failure
US11285283B2 (en)2016-05-032022-03-29Pneuma Respiratory, Inc.Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device
US11285284B2 (en)2016-05-032022-03-29Pneuma Respiratory, Inc.Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency
WO2017192774A1 (en)2016-05-032017-11-09Pneuma Respiratory, Inc.Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device
CA3022916C (en)2016-05-032020-03-10Pneuma Respiratory, Inc.Droplet delivery device for delivery of fluids to the pulmonary system and methods of use
JP2019523109A (en)*2016-05-032019-08-22ニューマ・リスパイラトリー・インコーポレイテッド Systems and methods for lung health management
WO2017192782A1 (en)2016-05-032017-11-09Pneuma Respiratory, Inc.Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment
WO2017212995A1 (en)2016-06-092017-12-14コニカミノルタ株式会社Device, method, and system for monitoring monitored person
US10376221B2 (en)*2016-07-062019-08-13Biosense Webster (Israel) Ltd.Automatic creation of multiple electroanatomic maps
KR101897065B1 (en)*2016-07-202018-09-12한국과학기술연구원Carpet System using Smart Fabric
WO2018068084A1 (en)2016-10-112018-04-19Resmed LimitedApparatus and methods for screening, diagnosis and monitoring of respiratory disorders
GB2569936B (en)*2016-10-142021-12-01Facense LtdCalculating respiratory parameters from thermal measurements
KR102087583B1 (en)*2016-10-182020-03-11한국전자통신연구원Apparatus and method for detecting abnormal respiration
CN110325110B (en)2016-11-102022-08-09纽约州立大学研究基金会Systems, methods, and biomarkers for airway obstruction
US10898107B2 (en)2016-11-112021-01-26Tata Consultancy Services LimitedSystem and method for pulmonary health monitoring
JP7186174B2 (en)*2016-12-052022-12-08メディパインズ コーポレイション Systems and methods for respiration measurements using respiratory gas samples
KR101917313B1 (en)*2017-01-262018-11-12(주)더블유알티랩Method and appratus for adaptively configuring threshold for object detectioin using radar
US10709349B2 (en)*2017-04-182020-07-14Boston Scientific Scimed Inc.Annotation waveform
US10321837B2 (en)*2017-04-282019-06-18Biosense Webster (Israel) Ltd.ECG machine including filter for feature detection
CN110799231B (en)2017-05-192022-08-02精呼吸股份有限公司Dry powder conveying device and using method thereof
EP3424418B1 (en)*2017-07-052023-11-08Stichting IMEC NederlandA method and a system for detecting a vital sign of a subject
EP3658021B1 (en)*2017-07-262024-02-07Thorasys Thoracic Medical Systems Inc.Method and system to acquire oscillometry measurements
IT201700093172A1 (en)*2017-08-112019-02-11Restech S R L METHOD FOR THE EARLY IDENTIFICATION OF REPUTATION OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY
US20190053754A1 (en)2017-08-182019-02-21Fitbit, Inc.Automated detection of breathing disturbances
US11723579B2 (en)2017-09-192023-08-15Neuroenhancement Lab, LLCMethod and apparatus for neuroenhancement
CN107744392A (en)*2017-09-282018-03-02惠州Tcl家电集团有限公司Adnormal respiration monitoring method, device and computer-readable recording medium
CN111526914A (en)2017-10-042020-08-11精呼吸股份有限公司Electronic respiration actuated linear liquid drop conveying device and using method thereof
CA3079189A1 (en)2017-10-172019-04-25Pneuma Respiratory, Inc.Nasal drug delivery apparatus and methods of use
JP2021502178A (en)2017-11-082021-01-28ニューマ・リスパイラトリー・インコーポレイテッド In-line droplet delivery device with a small volume ampoule and electrically actuated by breathing and how to use
US11717686B2 (en)2017-12-042023-08-08Neuroenhancement Lab, LLCMethod and apparatus for neuroenhancement to facilitate learning and performance
US10573155B2 (en)*2017-12-072020-02-25Covidien LpClosed loop alarm management
US11615688B2 (en)2017-12-222023-03-28Resmed Sensor Technologies LimitedApparatus, system, and method for motion sensing
WO2019122412A1 (en)2017-12-222019-06-27Resmed Sensor Technologies LimitedApparatus, system, and method for health and medical sensing
WO2019122414A1 (en)2017-12-222019-06-27Resmed Sensor Technologies LimitedApparatus, system, and method for physiological sensing in vehicles
CN108304912B (en)*2017-12-292020-12-29北京理工大学 A system and method for supervised learning of spiking neural networks using inhibitory signals
US12280219B2 (en)2017-12-312025-04-22NeuroLight, Inc.Method and apparatus for neuroenhancement to enhance emotional response
US11273283B2 (en)2017-12-312022-03-15Neuroenhancement Lab, LLCMethod and apparatus for neuroenhancement to enhance emotional response
EP3738126A1 (en)*2018-01-122020-11-18Cardiac Pacemakers, Inc.Discharge readiness assessment
JP7006296B2 (en)*2018-01-192022-01-24富士通株式会社 Learning programs, learning methods and learning devices
WO2019161065A1 (en)2018-02-162019-08-22University Of Louisville Research Foundation, Inc.Respiratory training and airway pressure monitoring device
JP6944402B2 (en)*2018-03-082021-10-06パナソニック インテレクチュアル プロパティ コーポレーション オブ アメリカPanasonic Intellectual Property Corporation of America Absence determination method, program, sensor processing system, and sensor system
KR20200133246A (en)2018-03-142020-11-26크로놀라이프 System and method for processing multiple signals
CN112040849B (en)2018-04-132024-01-02深圳市长桑技术有限公司System and method for determining blood pressure of a subject
US11364361B2 (en)2018-04-202022-06-21Neuroenhancement Lab, LLCSystem and method for inducing sleep by transplanting mental states
WO2019226956A1 (en)*2018-05-232019-11-28University Of WashingtonRespiratory failure detection systems and associated methods
CN109009222A (en)*2018-06-192018-12-18杨成伟Intelligent evaluation diagnostic method and system towards heart disease type and severity
US11638795B2 (en)*2018-06-292023-05-02Koninklijke Philips N.V.System and method for providing enhanced PAP metrics
US12023149B2 (en)2018-07-022024-07-023M Innovative Properties CompanySensing system and method for monitoring time-dependent processes
EP3591663A1 (en)*2018-07-062020-01-08Koninklijke Philips N.V.Computer aided diagnosis and monitoring of heart failure patients
US12419537B2 (en)2018-07-312025-09-23The Trustees Of Dartmouth CollegeDevice for automatically detecting lung function variability
JP6626543B2 (en)*2018-08-172019-12-25パラマウントベッド株式会社 Respiratory disorder determining apparatus and respiratory disorder determining method
WO2020037599A1 (en)*2018-08-232020-02-27深圳迈瑞生物医疗电子股份有限公司Medical device, apnea event monitoring method and apparatus
EP3849410A4 (en)2018-09-142022-11-02Neuroenhancement Lab, LLC SLEEP ENHANCEMENT SYSTEM AND METHOD
US11484256B2 (en)*2018-10-012022-11-01Koninklijke Philips N.V.Systems and methods for sleep staging
CN113383395B (en)*2018-10-222025-02-14皇家飞利浦有限公司 A decision support software system for sleep disorder identification
CN109602414B (en)*2018-11-122022-01-28安徽心之声医疗科技有限公司Multi-view-angle conversion electrocardiosignal data enhancement method
EP3883468A2 (en)*2018-11-192021-09-29ResMed Sensor Technologies LimitedMethods and apparatus for detection of disordered breathing
JP7466548B2 (en)*2019-01-292024-04-12コーニンクレッカ フィリップス エヌ ヴェ Apparatus and system for generating a respiratory alarm
EP3695776A1 (en)*2019-02-132020-08-19Koninklijke Philips N.V.A method and system for generating a respiration instability signal
CN110151156B (en)*2019-04-072021-10-29西安电子科技大学 A method and system for extracting fetal heart rate based on automatic weighted average algorithm within a window
US11464446B2 (en)*2019-04-172022-10-11Mediatek Inc.Physiological status monitoring apparatus and method
JP7543309B2 (en)2019-05-022024-09-02トゥウェルブ メディカル インコーポレイテッド Systems and methods for improving sleep disordered breathing
CN113785364A (en)*2019-05-022021-12-10月亮工厂公司System for measuring respiration and adjusting respiratory movement
US11786694B2 (en)2019-05-242023-10-17NeuroLight, Inc.Device, method, and app for facilitating sleep
US11488702B2 (en)*2019-07-182022-11-01Physiq, Inc.System and method for improving cardiovascular health of humans
US11134900B2 (en)*2019-07-232021-10-05KMZ Holdings LLCSystem and method for diagnostic analysis of human body systems, organs, and cells
JP7205433B2 (en)*2019-09-242023-01-17カシオ計算機株式会社 State estimation device, state estimation method and program
EP4037549A1 (en)*2019-09-302022-08-10Mari Co., Ltd.Apparatus and method for snoring sound detection based on sound analysis
US11420061B2 (en)2019-10-152022-08-23Xii Medical, Inc.Biased neuromodulation lead and method of using same
EP4051351A1 (en)*2019-10-312022-09-07ResMed Sensor Technologies LimitedSystems and methods for injecting substances into a respiratory system
GB2628495B (en)*2019-11-042024-12-11Fisher & Paykel Healthcare LtdBreathing assistance apparatuses and/or components thereof and/or uses thereof
US11819335B2 (en)2019-11-302023-11-21Resmed Sensor Technologies LimitedSystems and methods for adjusting user position using multi-compartment bladders
EP4076175A1 (en)*2019-12-182022-10-26Koninklijke Philips N.V.System and method for detecting respiratory information using contact sensor
CN115308734A (en)*2019-12-262022-11-08华为技术有限公司Respiratory data calculation method and related equipment
AU2021212395A1 (en)*2020-01-312022-08-25Resmed Sensor Technologies LimitedSleep status detection for apnea-hypopnea index calculation
CN115244624A (en)*2020-01-312022-10-25瑞思迈传感器技术有限公司 System and method for requesting data consent
CA3171828C (en)*2020-02-262024-01-02Novaresp Technologies Inc.Method and apparatus for determining and/or predicting sleep and respiratory behaviours for management of airway pressure
EP3875026A1 (en)*2020-03-032021-09-08Koninklijke Philips N.V.Sleep apnea detection system and method
RU2020113220A (en)*2020-04-092021-10-11Общество с ограниченной ответственностью «Парма-Телеком» HUMAN HEALTH RISK ASSESSMENT METHOD
US12193795B2 (en)2020-04-102025-01-14Norbert Health, Inc.Contactless sensor-driven device, system, and method enabling ambient health monitoring and predictive assessment
CN111462863B (en)*2020-04-142023-06-13赣州市全标生物科技有限公司Nutritional self-checking and meal recommending method and system
WO2021249858A1 (en)*2020-06-102021-12-16Koninklijke Philips N.V.Methods and systems for searching an ecg database
EP3944250A1 (en)*2020-07-222022-01-26Koninklijke Philips N.V.Methods and systems for searching an ecg database
WO2022024010A1 (en)*2020-07-302022-02-03ResMed Pty LtdSystems and methods for determining a health condition on a device local to a respiratory system user
TWI785378B (en)*2020-09-032022-12-01雲云科技股份有限公司Optical image physiological monitoring system with radar detection assistance
CN112043251B (en)*2020-09-302021-05-25深圳市艾利特医疗科技有限公司Cardiopulmonary function assessment method, device, equipment, storage medium and system under dynamic and static switching
US12263342B2 (en)*2020-11-042025-04-01The Alfred E. Mann Foundation For Scientific ResearchSensors and methods for determining respiration
US12009087B2 (en)2020-11-182024-06-11Evernorth Strategic Development, Inc.Predictive modeling for mental health management
US12249414B2 (en)2020-11-182025-03-11Evernorth Strategic Development, Inc.Mental health predictive model management system
CN112381233A (en)*2020-11-202021-02-19北京百度网讯科技有限公司Data compression method and device, electronic equipment and storage medium
CN112598033B (en)*2020-12-092022-08-30兰州大学Physiological signal processing method, device, equipment and storage medium
US11691010B2 (en)2021-01-132023-07-04Xii Medical, Inc.Systems and methods for improving sleep disordered breathing
CN112932457B (en)*2021-01-262022-11-25四川大学Respiratory system health monitoring device
US20240108834A1 (en)*2021-02-092024-04-04Halare, Inc.Multi-therapy systems, methods and apparatuses for the alleviation of sleep disordered breathing
US20240324970A1 (en)*2021-04-302024-10-03Medtronic, Inc.Sensing respiration parameters as indicator of sudden cardiac arrest event
USD1014517S1 (en)2021-05-052024-02-13Fisher & Paykel Healthcare LimitedDisplay screen or portion thereof with graphical user interface
CN112990789B (en)*2021-05-102021-11-02明品云(北京)数据科技有限公司User health risk analysis system
US11847127B2 (en)2021-05-122023-12-19Toyota Research Institute, Inc.Device and method for discovering causal patterns
FR3123795B1 (en)*2021-06-102025-03-21Valeo Systemes Thermiques Help system to provide diagnostic information
KR20240037245A (en)2021-06-222024-03-21뉴마 레스퍼러토리 인코포레이티드 Droplet delivery device by push ejection
CN113368403B (en)*2021-06-242022-01-04深圳市恒康泰医疗科技有限公司Intelligent physiotherapy system capable of improving cardio-pulmonary function
AU2021107064B4 (en)*2021-08-242022-08-25Rudder Technology Pty LtdNon-contact human respiration detection with radar signals
EP4147635B1 (en)*2021-09-092025-01-01Bitsensing Inc.Device, method and computer program for analyzing sleep breathing using radar
CN115804581B (en)*2021-09-152023-12-15深圳先进技术研究院Measuring method of heart rate characteristics, symptom detecting method and related equipment
KR102451624B1 (en)*2021-10-052022-10-11연세대학교 산학협력단Cardiovascular disease risk analysis system and method considering sleep apnea factors
CN113892931B (en)*2021-10-142023-08-22重庆大学Method for extracting and analyzing intra-abdominal pressure by FMCW radar based on deep learning
AU2022385572A1 (en)*2021-11-152024-05-16Fisher & Paykel Healthcare LimitedData capture, processing, storage and rendering system for breathing assistance apparatus
CN113951869B (en)*2021-11-172024-05-28上海跃扬医疗科技有限公司Respiratory disorder detection method, device, equipment and medium
KR102840526B1 (en)*2022-03-082025-07-31영남대학교 산학협력단Method and system for providing health information based on bio-signal measured by non-contact manner
IL315680A (en)*2022-03-182024-11-01Ohio State Innovation FoundationMobile ultrawideband radar for monitoring thoracic fluid levels and cardio-respiratory function
CN114778699A (en)*2022-03-292022-07-22哈尔滨工业大学 An online non-destructive monitoring method for fine grinding based on acoustic emission technology
KR20250038748A (en)2022-07-182025-03-19뉴마 레스퍼러토리 인코포레이티드 Small step size and high resolution aerosol generation system and method
CN115462780A (en)*2022-09-142022-12-13上海联影医疗科技股份有限公司 Supplementary method, device, computer equipment and storage medium for respiratory signal labeling
CN120129490A (en)*2022-09-282025-06-10脉冲健康有限责任公司 Wearable biosignal devices and systems for personalized therapeutic feedback
US11874271B1 (en)*2022-10-042024-01-16Gmeci, LlcApparatus and method for human performance exhalation sensing
WO2024252374A1 (en)*2023-06-082024-12-12Nox Medical EhfMethods, apparatuses, and systems for determining a physiological effectiveness of an airway pressure device
CN117503153B (en)*2024-01-052024-03-15北华大学 Artificial intelligence-based patient recovery evaluation method
CN117860241B (en)*2024-03-112024-06-11简阳市人民医院Self-management behavior monitoring method and system for acute myocardial infarction patient
CN120431677B (en)*2025-07-082025-09-16运城市恩光科技有限公司 Collaborative emergency response method, system and equipment based on smart wearable devices

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE3276924D1 (en)1981-04-241987-09-17Somed Pty LtdDevice for treating snoring sickness
DE3401841A1 (en)1984-01-201985-07-25Drägerwerk AG, 2400 Lübeck VENTILATION SYSTEM AND OPERATING METHOD THEREFOR
US5522382A (en)1987-06-261996-06-04Rescare LimitedDevice and method for treating obstructed breathing having a delay/ramp feature
EP0927538B1 (en)1993-11-052004-04-07Resmed LimitedDetermination of airway patency
US5738102A (en)*1994-03-311998-04-14Lemelson; Jerome H.Patient monitoring system
AUPN236595A0 (en)1995-04-111995-05-11Rescare LimitedMonitoring of apneic arousals
AUPO247496A0 (en)1996-09-231996-10-17Resmed LimitedAssisted ventilation to match patient respiratory need
JP2001525706A (en)1997-05-162001-12-11レスメッド・リミテッド Respiratory analysis system
AUPP366398A0 (en)1998-05-221998-06-18Resmed LimitedVentilatory assistance for treatment of cardiac failure and cheyne-stokes breathing
JP3688994B2 (en)1998-06-032005-08-31スコット・ラボラトリーズ・インコーポレイテッド Sedation device, device for delivering medication to a patient, and integrated patient interface device
US7308894B2 (en)1998-06-032007-12-18Scott Laboratories, Inc.Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics
US6390091B1 (en)1999-02-032002-05-21University Of FloridaMethod and apparatus for controlling a medical ventilator
US6367475B1 (en)1999-04-022002-04-09Korr Medical Technologies, Inc.Respiratory flow meter and methods of use
US7593952B2 (en)1999-04-092009-09-22Soll Andrew HEnhanced medical treatment system
US20060030890A1 (en)*1999-04-162006-02-09Cosentino Daniel LSystem, method, and apparatus for automated interactive verification of an alert generated by a patient monitoring device
AU5200600A (en)1999-06-162001-01-09Resmed LimitedApparatus with automatic respiration monitoring and display
US6600949B1 (en)1999-11-102003-07-29Pacesetter, Inc.Method for monitoring heart failure via respiratory patterns
US6398728B1 (en)1999-11-162002-06-04Cardiac Intelligence CorporationAutomated collection and analysis patient care system and method for diagnosing and monitoring respiratory insufficiency and outcomes thereof
FR2804405B1 (en)2000-01-282002-05-10Schmalbach Lubeca METHOD AND APPARATUS FOR STORING PLASTIC PREFORMS IN A CONTAINER, PROCESS AND INSTALLATION FOR MANUFACTURING AND STORAGE OF PLASTIC PREFORMS
US6644312B2 (en)2000-03-072003-11-11Resmed LimitedDetermining suitable ventilator settings for patients with alveolar hypoventilation during sleep
US6752151B2 (en)*2000-09-252004-06-22Respironics, Inc.Method and apparatus for providing variable positive airway pressure
EP1349491B1 (en)*2000-12-072013-04-17Children's Medical Center CorporationAutomated interpretive medical care system
US20030014222A1 (en)2001-02-282003-01-16Klass David B.Method and system for monitoring patient care
WO2003038566A2 (en)2001-11-012003-05-08Scott Laboratories, Inc.User interface for sedation and analgesia delivery systems and methods
US20040122487A1 (en)2002-12-182004-06-24John HatlestadAdvanced patient management with composite parameter indices
JP3872371B2 (en)2002-03-292007-01-24セイコーインスツル株式会社 Portable biological information collecting apparatus, biological information collecting system, and biological information collecting method
AU2003262625A1 (en)*2002-08-012004-02-23California Institute Of TechnologyRemote-sensing method and device
UA90651C2 (en)*2002-10-092010-05-25Компьюмедикс ЛимитедMethod and apparatus for maintaining and monitoring sleep quality during therapeutic treatments
DE10248590B4 (en)2002-10-172016-10-27Resmed R&D Germany Gmbh Method and device for carrying out a signal-processing observation of a measurement signal associated with the respiratory activity of a person
US7438686B2 (en)*2003-01-102008-10-21Medtronic, Inc.Apparatus and method for monitoring for disordered breathing
JP4750032B2 (en)*2003-08-182011-08-17カーディアック ペースメイカーズ, インコーポレイテッド Medical device
CN1901959B (en)2003-12-292010-05-12雷斯梅德有限公司 Mechanical ventilation in sleep-disordered breathing
JP4753881B2 (en)2004-01-162011-08-24コンプメディクス リミテッド Apparatus and signal processing method for monitoring, detecting and classifying sleep disordered breathing derived from electrocardiogram
US8403865B2 (en)*2004-02-052013-03-26Earlysense Ltd.Prediction and monitoring of clinical episodes
US20070118054A1 (en)*2005-11-012007-05-24Earlysense Ltd.Methods and systems for monitoring patients for clinical episodes
NZ581725A (en)2004-02-112011-06-30Resmed LtdSession-by-session adjustment of a device for treating sleep disordered breathing
SE0400378D0 (en)*2004-02-172004-02-17Jan Hedner Methods to treat and diagnose respiratory disorders in sleep and agents to perform the procedure
WO2005096729A2 (en)2004-03-312005-10-20Resmed LimitedMethods and apparatus for monitoring the cardiovascular condition of patients with sleep disordered breathing
US7878198B2 (en)2004-03-312011-02-01Michael FarrellMethods and apparatus for monitoring the cardiovascular condition of patients with sleep disordered breathing
NZ589369A (en)2004-10-062012-03-30Resmed LtdUsing oximeter and airflow signals to process two signals and with further processor to generate results based on the two signals
US20060089542A1 (en)2004-10-252006-04-27Safe And Sound Solutions, Inc.Mobile patient monitoring system with automatic data alerts
ATE526872T1 (en)*2004-11-022011-10-15Univ Dublin SLEEP MONITORING SYSTEM
US7578793B2 (en)*2004-11-222009-08-25Widemed Ltd.Sleep staging based on cardio-respiratory signals
EP1816948A2 (en)2004-11-232007-08-15Philips Intellectual Property & Standards GmbHDepression detection system
EP2377462A3 (en)*2004-12-232012-01-11ResMed Ltd.Apparatus for detecting and discriminating breathing patterns from respiratory signals
US20090054741A1 (en)*2005-03-292009-02-26Inverness Medical Switzerland GmbhDevice and method of monitoring a patient
US20090048500A1 (en)*2005-04-202009-02-19Respimetrix, Inc.Method for using a non-invasive cardiac and respiratory monitoring system
US20070055115A1 (en)*2005-09-082007-03-08Jonathan KwokCharacterization of sleep disorders using composite patient data
US20070193582A1 (en)*2006-02-172007-08-23Resmed LimitedTouchless control system for breathing apparatus
US20110263997A1 (en)2006-04-202011-10-27Engineered Vigilance, LlcSystem and method for remotely diagnosing and managing treatment of restrictive and obstructive lung disease and cardiopulmonary disorders
US7551078B2 (en)2006-05-082009-06-23Ihc Intellectual Asset Management, LlcDevice alert system and method
CN101489478B (en)*2006-06-012012-07-04必安康医疗有限公司 Devices, systems and methods for monitoring physiological symptoms
DE102007039004A1 (en)2006-08-302008-03-20Weinmann Geräte für Medizin GmbH + Co. KGRespiration parameter e.g. respiratory flow increase, capturing method for e.g. bi-level respirator assistance device, involves measuring respiratory gas flow, respiratory gas pressure, oxygen saturation or their combination as state value
WO2008135985A1 (en)*2007-05-022008-11-13Earlysense LtdMonitoring, predicting and treating clinical episodes
CA2696773A1 (en)2007-08-232009-02-26Invacare CorporationMethod and apparatus for adjusting desired pressure in positive airway pressure devices
JP5115704B2 (en)2007-10-312013-01-09株式会社エクォス・リサーチ Steering
US7808395B2 (en)*2007-11-092010-10-05Emfit OyOccupancy detecting method and system
US20100152600A1 (en)*2008-04-032010-06-17Kai Sensors, Inc.Non-contact physiologic motion sensors and methods for use
CN102046076A (en)*2008-04-032011-05-04Kai医药公司 Non-contact physiological motion sensor and method of use thereof
JP5596670B2 (en)2008-05-092014-09-24コーニンクレッカ フィリップス エヌ ヴェ Non-contact respiratory monitoring of patients
CN102113034A (en)*2008-05-122011-06-29阿列森斯有限公司 Monitor, predict and manage clinical episodes
US8298153B2 (en)*2008-07-092012-10-30Medtronic, Inc.System and method for the detection of acute myocardial infarction
US8417463B2 (en)2008-07-222013-04-09Cardiac Pacemakers, Inc.Systems and methods for monitoring pulmonary edema dynamics
US8844525B2 (en)2008-07-252014-09-30Resmed LimitedMethod and apparatus for detecting and treating heart failure
US10891356B2 (en)2008-09-242021-01-12Resmed Sensor Technologies LimitedContactless and minimal-contact monitoring of quality of life parameters for assessment and intervention
WO2010042872A2 (en)2008-10-122010-04-15University Of Maryland, BaltimorePredetermined presentation of patient data at bedside
US9526429B2 (en)*2009-02-062016-12-27Resmed Sensor Technologies LimitedApparatus, system and method for chronic disease monitoring
AU2010201032B2 (en)2009-04-292014-11-20Resmed LimitedMethods and Apparatus for Detecting and Treating Respiratory Insufficiency
US8478538B2 (en)*2009-05-072013-07-02Nellcor Puritan Bennett IrelandSelection of signal regions for parameter extraction
US10105506B2 (en)2009-07-142018-10-23Resmed LimitedSetup automation for respiratory treatment apparatus
GB2471902A (en)2009-07-172011-01-19Sharp KkSleep management system which correlates sleep and performance data
US8884813B2 (en)2010-01-052014-11-11The Invention Science Fund I, LlcSurveillance of stress conditions of persons using micro-impulse radar
US8862195B2 (en)*2010-03-102014-10-14University Of ValladolidMethod, system, and apparatus for automatic detection of obstructive sleep apnea from oxygen saturation recordings
WO2011141916A1 (en)2010-05-132011-11-17Sensewiser Ltd.Contactless non-invasive analyzer of breathing sounds
WO2011143631A2 (en)*2010-05-142011-11-17Kai Medical, Inc.Systems and methods for non-contact multiparameter vital signs monitoring, apnea therapy, sway cancellation, patient identification, and subject monitoring sensors
US8695591B2 (en)*2010-05-262014-04-15Lloyd Verner OlsonApparatus and method of monitoring and responding to respiratory depression
US20120041771A1 (en)*2010-08-112012-02-16Cosentino Daniel LSystems, methods, and computer program products for patient monitoring
IT1401645B1 (en)2010-09-102013-08-02Milano Politecnico SYSTEM FOR THE AUTOMATIC ASSESSMENT OF RESPIRATORY DISEASES AND FOR THE PREDICTION OF ACUTE FUTURE INSTABILITY OF AIRWAYS
US20120138533A1 (en)2010-12-012012-06-07Curtis James RDialysis system control system with user interface
CN102415879A (en)*2011-09-092012-04-18北京大学深圳研究生院Sleep monitoring device based on piezoelectric film sensor
GB201116860D0 (en)2011-09-302011-11-09Guy S And St Thomas Nhs Foundation TrustPatent monitoring method and monitoring device
JP6655991B2 (en)*2012-05-302020-03-04レスメッド センサー テクノロジーズ リミテッド Method and apparatus for monitoring cardiopulmonary health

Also Published As

Publication numberPublication date
JP6655991B2 (en)2020-03-04
JP7273774B2 (en)2023-05-15
WO2013177621A9 (en)2014-02-13
JP2018153661A (en)2018-10-04
US20150164375A1 (en)2015-06-18
CN110720918A (en)2020-01-24
US20240164726A1 (en)2024-05-23
JP2021035521A (en)2021-03-04
AU2017200083A1 (en)2017-02-02
JP2015522314A (en)2015-08-06
EP2854636B1 (en)2019-08-21
CN115813368A (en)2023-03-21
JP6787947B2 (en)2020-11-18
EP3639733A2 (en)2020-04-22
US20200113484A1 (en)2020-04-16
EP2854636A4 (en)2016-02-24
CN104736055A (en)2015-06-24
AU2017200083B2 (en)2019-07-11
JP2023099124A (en)2023-07-11
EP3639733A3 (en)2020-07-29
WO2013177621A1 (en)2013-12-05
EP2854636A1 (en)2015-04-08
US10426380B2 (en)2019-10-01
CN110720918B (en)2023-01-10
AU2013270443A1 (en)2014-12-18
AU2013270443B2 (en)2016-10-13
US11850077B2 (en)2023-12-26
EP4154804A1 (en)2023-03-29

Similar Documents

PublicationPublication DateTitle
US20240164726A1 (en)Method and apparatus for monitoring cardio-pulmonary health
US12245870B2 (en)Methods and apparatus for monitoring chronic disease
US20230190140A1 (en)Methods and apparatus for detection and monitoring of health parameters
US12350034B2 (en)Methods and apparatus for detection of disordered breathing
US11980484B2 (en)Systems and methods for monitoring and management of chronic disease
US20250128003A1 (en)Systems and methods for screening, diagnosis, detection, monitoring and/or therapy

Legal Events

DateCodeTitleDescription
PUAIPublic reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text:ORIGINAL CODE: 0009012

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: THE APPLICATION HAS BEEN PUBLISHED

ACDivisional application: reference to earlier application

Ref document number:2854636

Country of ref document:EP

Kind code of ref document:P

AKDesignated contracting states

Kind code of ref document:A2

Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUALSearch report despatched

Free format text:ORIGINAL CODE: 0009013

AKDesignated contracting states

Kind code of ref document:A3

Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1Information provided on ipc code assigned before grant

Ipc:A61B 5/00 20060101AFI20200622BHEP

Ipc:A61B 5/08 20060101ALI20200622BHEP

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: REQUEST FOR EXAMINATION WAS MADE

17PRequest for examination filed

Effective date:20210129

RBVDesignated contracting states (corrected)

Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: EXAMINATION IS IN PROGRESS

17QFirst examination report despatched

Effective date:20211210

GRAPDespatch of communication of intention to grant a patent

Free format text:ORIGINAL CODE: EPIDOSNIGR1

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: GRANT OF PATENT IS INTENDED

INTGIntention to grant announced

Effective date:20220512

GRASGrant fee paid

Free format text:ORIGINAL CODE: EPIDOSNIGR3

GRAA(expected) grant

Free format text:ORIGINAL CODE: 0009210

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: THE PATENT HAS BEEN GRANTED

ACDivisional application: reference to earlier application

Ref document number:2854636

Country of ref document:EP

Kind code of ref document:P

AKDesignated contracting states

Kind code of ref document:B1

Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP3Party data changed (applicant data changed or rights of an application transferred)

Owner name:RESMED SENSOR TECHNOLOGIES LIMITED

REGReference to a national code

Ref country code:GB

Ref legal event code:FG4D

RIN1Information on inventor provided before grant (corrected)

Inventor name:REDMOND, STEPHEN JAMES

Inventor name:O'HARE, EMER

Inventor name:CELKA, PATRICK

Inventor name:FOX, NIALL

Inventor name:ZAFFARONI, ALBERTO

Inventor name:DE CHAZAL, PHILIP

Inventor name:HENEGHAN, CONOR

Inventor name:KHUSHABA, RAMI

Inventor name:JAVED, FAIZAN

Inventor name:COLEFAX, MICHAEL WACLAW

Inventor name:FARRUGIA, STEVEN PAUL

Inventor name:SCHINDHELM, KLAUS HENRY

REGReference to a national code

Ref country code:CH

Ref legal event code:EP

REGReference to a national code

Ref country code:AT

Ref legal event code:REF

Ref document number:1526455

Country of ref document:AT

Kind code of ref document:T

Effective date:20221115

REGReference to a national code

Ref country code:DE

Ref legal event code:R096

Ref document number:602013082773

Country of ref document:DE

REGReference to a national code

Ref country code:IE

Ref legal event code:FG4D

REGReference to a national code

Ref country code:LT

Ref legal event code:MG9D

REGReference to a national code

Ref country code:NL

Ref legal event code:MP

Effective date:20221026

REGReference to a national code

Ref country code:AT

Ref legal event code:MK05

Ref document number:1526455

Country of ref document:AT

Kind code of ref document:T

Effective date:20221026

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:NL

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:SE

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:PT

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20230227

Ref country code:NO

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20230126

Ref country code:LT

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:FI

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:ES

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:AT

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:RS

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:PL

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:LV

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:IS

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20230226

Ref country code:HR

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:GR

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20230127

P01Opt-out of the competence of the unified patent court (upc) registered

Effective date:20230523

REGReference to a national code

Ref country code:DE

Ref legal event code:R097

Ref document number:602013082773

Country of ref document:DE

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:SM

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:RO

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:EE

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:DK

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:CZ

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:SK

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:AL

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

PLBENo opposition filed within time limit

Free format text:ORIGINAL CODE: 0009261

STAAInformation on the status of an ep patent application or granted ep patent

Free format text:STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26NNo opposition filed

Effective date:20230727

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:SI

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

REGReference to a national code

Ref country code:CH

Ref legal event code:PL

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:MC

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

REGReference to a national code

Ref country code:BE

Ref legal event code:MM

Effective date:20230531

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:MC

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:LU

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20230530

Ref country code:LI

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20230531

Ref country code:CH

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20230531

REGReference to a national code

Ref country code:IE

Ref legal event code:MM4A

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:IE

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20230530

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:IE

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20230530

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:IT

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

Ref country code:BE

Free format text:LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date:20230531

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:BG

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:BG

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date:20221026

PGFPAnnual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code:DE

Payment date:20250423

Year of fee payment:13

PGFPAnnual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code:GB

Payment date:20250423

Year of fee payment:13

PGFPAnnual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code:FR

Payment date:20250423

Year of fee payment:13

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:CY

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date:20130530

PG25Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code:HU

Free format text:LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date:20130530


[8]ページ先頭

©2009-2025 Movatter.jp